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Positron emission tomography in oncology
 
Positron Emission Tomography (PET) is the study and visualization of human physiology by 
electronic detection of short-lived positron emitting radiopharmaceuticals. It is the only non-
invasive technology that can routinely and quantitatively measure metabolic, biochemical and 
functional activity in living tissue. This differs from other forms of imaging such as magnetic 
resonance imaging (MRI), computed tomography (CT) or ultrasound techniques, which 
mainly show structural (anatomical) information.
In cancer, the most common radiolabelled tracer is [18F]-fluoro-2-deoxy-D-glucose (FDG).  
Cancer cells have a much higher metabolic rate than other cells. One characteristic is that 
cancer cells need higher levels of glucose for energy. This is the biological process PET 
measures. Therefore FDG-PET allows differentiation between malignant and benign 
abnormalities.
PET can also help physicians monitor the treatment of disease. For example, chemotherapy 
leads to changes in cellular activity, and that may be observable by PET long before structural 
changes can be measured by ultrasound, X-rays, CT, or MRI.
Legend to the figure: Typical whole-body PET image of a patient with NSCLC. Apart from uptake in the 
lung and the mediastinum, there is physiological uptake in the brain and bladder. The most important finding 
was a metastases near the left kidney (most right image). Due to this finding, the planned policy (neoadjuvant 







In 2003 the results were published of a randomized controlled trial (RCT) comparing magnetic 
resonance imaging (MRI) with plain radiographs in patients that were referred to the hospital for 
radiographic evaluation of low back pain.1 Improvements in the MRI-technique had made the com-
parison a clinically relevant issue. Both imaging techniques resulted in nearly identical outcomes 
of disability, pain and general health status for patients. However, MRI increased the costs of care 
because of the higher costs of the technique itself and the increased number of operations and spe-
cialist consultations due to MRI.  Although physicians preferred using MRI, substituting MRI for 
radiographs in primary care of low back pain is not indicated.
 
In the ’90s, 18F-fluorodeoxyglucose (FDG)-
positron emission tomography (PET) emerged 
as a promising innovative imaging technique 
(see inlay). However, the technique is expen-
sive and for the time being its availability is 
limited. Therefore, to become of benefit for 
patients and society, PET needs to be evalu-
ated together and in contrast to other non- 
invasive techniques to define its most efficient 
indications.  
In general, the diagnosis of a disease, for example of a particular cancer, involves a multidisciplinary, 
step-by-step process. The goal of that process is to determine the most likely status of disease in order 
to give the patient the therapy that is most appropriate to that disease condition. Each test con-
tributes a piece of information. In diagnostic accuracy studies the information is usually expressed 
in a two-by-two table. The test is either positive or negative and the disease is present or absent. A 
series of statistics are based on these combinations. Sensitivity, the number of true test positives 
divided by all cases with disease and specificity, the number of true test negatives divided by all cases 
without disease, are the most common accuracy measures. In reality however, unless it is based on a 
pathognomonic sign of disease, a test will rarely result in such black-and-white condition. Recently, 
a radiologist, forced to express himself in a language that was not his, phrased it as ” Sitting on the 
fence – a radiologist’s stock in trade – necessitates using words for balance, weighing diagnostic 
probabilities, and leaning toward the heavier side. But because I couldn’t use the subjunctive mood, 
I was forced into the realm of apparent diagnostic certainty”.2 The result of a FDG-PET-scan is 
usually expressed qualitatively, e.g. in terms of normal, faint, moderate and intense. Translated into 
a diagnosis these qualifications should be interpreted somewhere between definitively benign, prob-
ably benign, equivocal, probably malignant or definitively malignant. Obviously, the dichotomy is 
lost. Likewise, each individual (non-invasive) test adds some probability measure and usually only 
invasively obtained tissue material provides histological proof of disease – in most cases. 
PET Scans a Clinical Reality 
If you could manage and treat your 
cancer patients more accurately 
45% of the time¹, you might call it 
a clinical breakthrough…
We call it PET. 
1 Tucker et al., Journal of Clinical Oncology –  
Vol. 19, No. 9, 2001, pp. 2504-2508.
Figure 1. Source: http://www.petscaninfo.com
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The following example may illustrate some of the uncertainties in a common diagnostic process: lung 
cancer often presents as a solitary pulmonary lesion (SPN). One third of lung nodules in patients 
more than 35 years old are found to be malignant. Over 50% of the radiographically indeterminable 
nodules resected at thoracoscopy are benign.3 The pretest probability of cancer determines the most 
cost-effective strategy for diagnosis of SPN. If the probability is very low, radiographic follow-up 
is preferred but more advanced and invasive techniques are needed when the pretest probability 
increases.4 The pretest probability may be expressed as function of patient characteristics such as age 
and smoking history and some radiographical parameters.5 Typically a technique such as FDG-PET 
may contribute to the diagnosis of SPN because it may help to distinguish benign from malignant 
abnormalities. In 2001, a meta-analysis was published on 40 diagnostic accuracy studies of FDG-
PET in SPN. The median sensitivity and specificity for pulmonary nodules were approximately 97% 
and 78% respectively.6 That makes it a very accurate test. However, whether FDG-PET is helpful 
in clinical decision making and actually will change subsequent patient management cannot be as-
certained with these values only, because the probability of malignancy after the test depends on its 
pretest probability (figure 2) and the overall interpretive analysis of the physicians, c.q. what are the 
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Figure 2. Posterior probability of malignancy related to prior probability using FDG-PET 
with a sensitivity of 97% and a specificity of 78%. Source: Gould, JAMA 2001 (6). 

















Figure 2. Posterior probability of malignancy related to prior probability using FDG-PET with a sensitivity of 





Staging of non-small-cell lung cancer and FDG-PET
The use of FDG-PET encompasses more potential benefits in a patient undergoing non-invasive 
evaluation of lung cancer than can be captured in a diagnostic accuracy study of solitary pulmonary 
lesions. There are 2 main categories of lung cancer: small cell lung cancer and non-small cell lung 
cancer (NSCLC). Yearly 9000 cases of lung cancer are diagnosed in the Netherlands, and of these 
80% have non-small cell lung cancer.7 Accurate staging of NSCLC cancer is very important because 
treatment options and the prognosis differ significantly by stage. Current diagnostic strategies are 
primarily aimed at selecting patients who are likely to benefit from surgery or multimodality treat-
ment. A recent study based on two hospitals in our own region and a large study from The USA in-
dicated that the pre-operative diagnostic process is suboptimal and too many patients are given the 
benefit of the doubt with surgery.8,9 Already at its introduction, FDG-PET appeared promising as a 
technique to improve the overall diagnostic process especially with respect to reducing unnecessary 
surgery. It proved more accurate than CT in detecting solitary pulmonary lesions,4,6 in detecting or 
evaluating mediastinal lymph nodes10,11 and in identifying distant metastasis. However, improved 
accuracy in different indications does not necessarily imply overall clinical usefulness, e.g. better 
patient management and improved clinical outcome. To prove (cost-)-effectiveness, a series of con-
ditions have to be met. First, the current diagnostic strategy should have shortcomings and the new 
test should likely be able to contribute relevant information to those deficiencies. Second, the infor-
mation from the new test should be relevant and sufficiently convincing to direct the clinician to 
alternative patient management. Such a change in management should in turn lead to an improved 
patient outcome at reasonable costs. 
The first condition, the potential residual inefficiency in daily clinical practice of preoperative stag-
ing in patients with suspected NSCLC was studied in two hospitals, one general and one academic 
institute, in our region of interest. It was found that nearly 50% of operated patients, surgical in-
tervention failed because of irresectable tumor or benign lesion at surgery or because the disease 
recurred or metastasized within one year.8 The second condition, the amount of relevant informa-
tion added by the new test would be best answered by a comparison of the concurrent strategy with 
a strategy that includes the new test, e.g. FDG-PET as add-on. To minimize potential bias in that 
comparison, due to measurable and non-measurable patient- and tumor characteristics and diagnos-
tician/clinician decisions, a randomized controlled trial is preferred, whenever feasible and ethical. 
Concurrent collection of information on costs in combination with decisions analysis can be used 
to prove cost-effectiveness of the new technology. Ultimately, a comparison of the situation before 
and after the introduction of a new technology after its implementation in routine care will allow a 
full assessment of the benefits and costs for patients and society.
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In other words, the assessment of the contribution of a diagnostic test to the patient management 
process is a multi-phase hierarchical process, as has been described by Fryback and others.12 The 
process starts with the technical aspects of the test such as image quality and reproducibility (level 
1) and is followed by the assessment of the diagnostic accuracy (level 2). Next, at the third level it is 
investigated whether the information produces indeed changes in the physicians’ diagnostic think-
ing. Such a change is a prerequisite for a change in patient management (level 4). At the fifth level, 
the actual size of effect on patient outcome is measured.  And finally, the cost-benefit analysis of the 
introduction of the technology is made (level 5). Clearly, demonstration of efficacy at each lower 
level is logically necessary, but not sufficient, to assure efficacy at a higher level. 
staging nsClC
 
The system most often used to describe the growth and spread of non-small cell lung cancer 
(NSCLC) is the tnm staging system, also known as the American Joint Committee on Can-
cer (AJCC) system. In TNM staging, information about the tumor, nearby lymph nodes, and 
distant organ metastases is combined and a stage is assigned to specific TNM groupings. The 
grouped stages are described using the number 0 and Roman numerals from I to IV.
t stands for tumor (its size and how far it has spread within the lung and to nearby organs), n 
stands for spread to lymph nodes, and m is for metastasis (spread to distant organs).
stage grouping for non-small cell lung cancer: Once the T, N, and M categories have been 
assigned, this information is combined (stage grouping) to assign an overall stage of 0, I, II, III, 
or IV. Patients with lower stage numbers have a more favorable outlook for survival.
overall stage t category n category m category
Stage 0 Tis (In situ) N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T1 N1 M0























Stage IV Any T Any N M1






This thesis is about the design of studies to evaluate PET as a novel diagnostic technology with em-
phasis on its potential role in NSCLC. The hierarchical approach act as the theoretical backbone 
and improved diagnostic accuracy of PET in NSCLC has been considered as point of departure. 
To explore and improve our understanding of the potential impact of FDG-PET on management 
decisions in the pre-operative setting, we first performed a ‘clinical value’ or before-after’ study in 
patients referred to the PET-center with a diagnostic NSCLC problem. The results are presented 
in chapter 2. For the purpose of designing the diagnostic RCT, we performed a literature search (in 
1996, which was reiterated in 2005) to find other randomized diagnostic imaging studies. Details of 
this search are described in chapter 3. Meanwhile, we designed our first RCT and the essentials of the 
protocol and the logistics are explained in chapter 4. The study got the name ‘PET in LUng cancer 
Staging’ (PLUS) and in chapter 5 the results of the PLUS study are shown. Because the data on costs 
of the work-up were collected concurrently, we were able to calculate the overall costs. In addition, 
different scenarios depending on tracer and scanning capacity were explored by means of sensitivity 
analysis in chapter 6. The need for randomization in a comparison of different diagnostic strategies 
to determine the added value of a diagnostic device is not appreciated by every researcher.  In chapter 
7 we formulated our point of view with respect to the role of randomization in diagnostic research. 
Finally, in chapter 8 an overview is given of studies undertaken along the hierarchy of the theoretical 
framework to evaluate FDG-PET. A summary of the thesis and some discussion on current develop-
ments can be found in chapter 9.
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A study was undertaken to investigate the effect of 18F-fluorodeoxyglucose (18FDG) positron 
emission tomography (PET) on diagnosis and management of clinically problematic patients 
with suspected non-small cell lung cancer (NSCLC). 
methods: 
A prospective before-after study in a cohort of all 164 patients (university / community set-
tings) referred for PET between August 1997 and July 1999. PET was restricted to cases where 
non-invasive tests failed to solve clinical problems. The impact on diagnostic understanding 
and management was assessed using questionnaires (intended treatment without PET, actual 
treatment choice after PET, post hoc clinical assessment).
results: 
Diagnostic problems especially pertained to unclear radiological findings (n = 112; 63%), medi-
astinal staging (n = 36; 20%) and distant staging issues (n = 16; 9%). PET findings were validat-
ed by reviewing medical records. PET had a positive influence on diagnostic understanding in 
84%. Improved diagnostic understanding solely based on PET was reported in 26%, according 
to referring physicians, PET resulted in beneficial change of therapy in 50%. Cancelled surgery 
was the most frequent therapy change after PET (35%). 
Conclusion: 
18FDG PET applied as “add-on” technology in patients with these clinical problems appears 
to be a clinically useful tool, directly improving therapy choice in 25% of patients. The value of 




Prospective use of serial questionnaires to evaluate the therapeutic effi
cacy of 18fdg pet in (suspected) lung cancer
introduction
Medical imaging technology is rapidly expanding and the role of each modality is being redefined 
constantly. Positron emission tomography (PET) using 18F-fluorodeoxyglucose (18FDG) has 
emerged as an accurate imaging modality in patients with lung cancer.1-3 Potential clinical indi-
cations include the differential diagnosis of benign versus malignant disease, initial (preoperative) 
staging, evaluation of suspected recurrences, and follow up after treatment. The use of PET in clini-
cal practice is based predominantly on studies of technical performance and diagnostic accuracy.4,5 
To ensure an appropriate use of PET, such studies should be followed by an analysis of the impact of 
PET on management decisions, outcomes of care, and cost-effectiveness. 
In the northwestern part of the Netherlands where this study was performed, a single PET scanner 
serves 2.7 million inhabitants, with 50% of its time slots available for clinical purposes. To restrict 
the use of PET to those patients that may benefit most, a program has been developed to evaluate 
the clinical usefulness of PET, investigating the cost-effectiveness of performing PET on a routine 
basis in the preoperative staging of non-small cell lung cancer (NSCLC)6 and its impact as an “add 
on” technique in specific problem cases. To measure the clinical value of PET in the latter group, we 
performed a prospective before-after study in a cohort of clinically problematic cases, typically after 
an extensive conventional work-up. This study design was used during the early studies of computed 
tomographic (CT) scanning by Wittenberg et al7 and allows a systematic assessment of the impact 
of a test on diagnostic understanding as well as on patient management within the clinical context.8 
methods
To be eligible for PET scanning, patients had to have suspected or proven NSCLC with a diagnostic 
problem which, according to the referring physician, could not be solved by conventional meth-
ods alone and in which the PET result might affect patient management. In an attempt to restrict 
PET scanning to such cases, referrals were only accepted after discussion of the case between this 
physician and the staff nuclear medicine physician in charge at the Clinical PET Centre of the VU 
University Medical Centre. PET scanning therefore typically followed an extensive conventional 
work-up. All patients routinely underwent laboratory tests, bronchoscopy, chest radiography and 
CT scanning extending from the neck to the upper abdomen (including liver and adrenal glands). 
Additional diagnostic tests were performed in cases with signs and symptoms suggestive of distant 
metastatic disease. Patients entered in randomized9 or response monitoring trials10 were not includ-
ed in the present report.
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Assessment of clinical value.
The impact of PET on diagnostic understanding, and therapy choice was investigated using three 
questionnaires (figure 1). These questionnaires were to be completed by the referring physician be-
fore PET scanning, shortly after PET scanning, and about 6 months after PET scanning, respec-
tively. In the first questionnaire, information was requested regarding the histological diagnosis (if 
known), a definition of the current diagnostic problem, a differential diagnostic consideration, the 
results of diagnostic tests already performed and any planned diagnostic tests. In addition, the refer-
ring physician was requested to outline the intended patient management plan if PET scanning was 
not available. The second questionnaire requested information regarding the working diagnosis and 
planned treatment after PET scanning in addition to any diagnostic tests that had been ordered as a 
direct consequence of the PET scan result. In the final questionnaire, the referring physician was re-
quested to convey the final diagnosis and to rate the overall usefulness of PET separately in terms of 
diagnostic understanding and therapy of choice according to the method of Wittenberg et al.7 This 
method involves using a 5 point ordinal scale (box 1), with higher scores representing an increasing 
positive impact. 
All questionnaires were checked for internal consistency between the pre-PET intentional manage-
ment (questionnaire 1) and post-PET actual management (questionnaire 3). In the case of inconsis-
tencies, the referring physicians were asked to review the cases in question and to revise the overall 
clinical value rating accordingly and these data were used in the analysis. In the case of PET negative 
– that is, suspected benign – coin lesions, follow-up was extended beyond 6 months by examining 
the medical records of these patients.
Preliminary guidelines* ‘Candidate for PET?’
(Telephone consultation)
Questionnaire 1 
• Current diagnosis 
• Diagnostic problem
• Result and planned diagnostic tests











• Final diagnosis (if known)





Figure 1. Study protocol.*





Prospective use of serial questionnaires to evaluate the therapeutic effi
cacy of 18fdg pet in (suspected) lung cancer
Management changes
Treatment (management) changes were considered “major” if treatment changed from one modal-
ity to another – for example, from medical to surgical/radiation/ no treatment or vice versa11 – and 
“minor” if treatment changed within a modality – for example, altered medical, surgical or radio-
therapy approach. 
PET imaging
Whole body 18FDG PET scans were performed with a dedicated PET scanner (ECAT EXACT 
HR+, CTI/Siemens). Emission scans, typically extending from mid-skull to mid-femur, were ac-
quired in 2D mode, approximately 60 minutes after intravenous injection of 370 MBq (10 mCi) 
18FDG. Patients were asked to fast for at least 6 hours prior to the PET study. Oral intake of water 
was encouraged. 
PET scans were corrected for decay, scatter and randoms. Scans were reconstructed as 128x128 ma-
trices using filtered back projection with a Hanning filter (cut-off 0.5 cycles/pixel) resulting in a 
transaxial spatial resolution of 7 mm at full width half maximum. If possible, CT scan data were 
used for more precise anatomical localization of PET abnormalities suspected as being malignant. 
Referring physicians were informed by telephone of the result of the PET scan and an advice to the 
next step. Clinicians were urged to verify clinically decisive PET findings by conventional means 
(histology, imaging, follow-up) and to ignore unconfirmed hot spots. PET findings were retrospec-
tively validated by examination of the medical records of the included patients. Histopathology and 
clinical follow up findings that showed a benign or malignant course were considered as a valid 
reference test. 
Diagnostic understanding (DU)
D = 1: PET confused my understanding of this patient’s disease and led to investigations I would not otherwise 
have done
D = 2: PET confused my understanding of this patient’s disease but did not lead to any additional investiga-
tions
D = 3: PET had little or no effect on my understanding of this patient’s disease
D = 4: PET provided information which substantially improved my understanding of this patient’s disease
D = 5: My understanding of this patient’s disease depended upon diagnostic information provided only by PET 
(unavailable from any other non-surgical procedure)
Treatment choice (TC) 
T = 1:  PET led me to choose treatment which in retrospect was not in the best interests of the patient
T = 2: PET was of no influence in my choice of treatment 
T = 3:  PET did not alter my choice of treatment but did increase my confidence in the choice
T = 4: PET contribute to a change in my chosen treatment but other factors (other imaging tests, other diag-
nostic tests, changes in patient status) were equally or more important
T = 5: PET was very important compared with other factors in leading to a beneficial change in treatment
Box 1. Questionnaire on evaluation of PET impact
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Statistical analysis
Differences in diagnostic understanding or treatment choice between the three indications were 
tested by means of a two sided Kruskal-Wallis test. Wilcoxon-Mann-Whitney test was used to test 
differences between two samples. Changes in treatment plans before and after PET were tested by 
the marginal homogeneity test.12 
results 
During a 23-month inclusion period, 179 patients with suspected NSCLC were referred for PET 
scanning. The referring physicians included pulmonologists (76%), oncologists (7%), internists 
(6%), radiotherapists (6%), neurologists (3%) and surgeons (1%) from 21 different university and 
community hospitals. Questionnaires were returned from 178 (99%) patients and a fully completed 
questionnaires (all questions answered) was obtained for 136 (76%) patients. Specifically, question-
naire 1 was fully completed for 83% of the patients, questionnaire 2 for 92%, and questionnaire 3 
for 98%. Indications for PET could be subdivided in six groups: unclear radiological abnormality 
(including solitary pulmonary nodules and lung masses, n = 112; 63%), staging of the mediastinum 
(n = 36; 20%), distant staging issues (n = 16; 9%), response monitoring (n = 5; 2.8%), suspected 
recurrence (n = 5; 2.8%), and unknown primary (n = 5; 2.8%). The present report focuses on the first 
three clinical indications.
In these 164 patients, the clinical work-up before PET included laboratory tests, chest radiography, 
CT scan of the chest (including liver and adrenal glands) and bronchoscopy. 
In patients with distant staging problems (n = 16) the work-up before PET consisted of bone scintig-
raphy and radiographic studies in the three patients with clinical concerns about skeletal metastases; 
CT evaluation of the abdomen typically preceded referrals with suspect adrenal enlargement or 
liver lesions in which biopsy was considered not feasible or had been inconclusive. In two patients in 
which chest CT scan had shown additional and indeterminate pulmonary lesions, bronchoscopic 
examination had been negative and it was not considered feasible to take biopsy specimens. In five 
patients with potentially solitary brain metastases, dissemination tests had included CT scanning 
(brain, chest, liver and adrenal glands) and bone scintigraphy. In general, the work-up of patients 
with unclear radiological findings before PET scanning conformed to national guidelines.13
The diagnostic problems concerning mediastinal staging leading to referral for PET (instead of in-
vasive mediastinal staging) included former mediastinoscopy, thoracotomy or radiotherapy, inde-
terminate invasive staging results, medical inoperability, and “to determine the most appropriate 
surgical approach”. After careful evaluation we were unable to identify a specific reason for choosing 
PET scanning as opposed to mediastinoscopy to determine mediastinal lymph node involvement 
in 10 patients. 
In 29 out of the 179 patients the initially formulated management plans (to be carried out if PET had 




Prospective use of serial questionnaires to evaluate the therapeutic effi
cacy of 18fdg pet in (suspected) lung cancer
the physician’s written plan before PET was to perform a thoracotomy, and a thoracotomy was in-
deed performed but treatment choice was rated as 5 (PET was very important compared with other 
factors leading to a beneficial change in treatment). Such inconsistent assessments were revised by 
the referring physicians (specifically with respect to the questionnaire 3), and corrected in 28 cases.
Du = 1 Du = 2 Du = 3 Du = 4 Du = 5 missing total
Radiological abnormality 3 6 12 61 29 1 112
Mediastinal staging 1 1 1 21 11 1 36
Distant staging 0 0 2 10 2 2 16
Overall 4 7 15 92 42 4 164
Table 1. The impact of PET on diagnostic understanding (DU) ratings (defined in box 1)
Diagnostic understanding 
The impact of PET on diagnostic understanding was analyzed for each clinical indication (table 1). 
Overall, PET was solely responsible for improved diagnostic understanding (DU = 5) in 26% (95% 
CI 19 to 33) of the patients and substantially contributed to diagnostic understanding (DU = 4) in 
58% (95% CI 50 to 65). The effect of the PET result on diagnostic understanding was confusing and 
led to additional tests (DU = 1) in 3% (95% CI 1 to 6), and had no or little effect (DU = 3) in 9% (95% 
CI 5 to 15). The impact of PET on diagnostic understanding was not significantly different for the 
three clinical indications (p = 0.45). There was no significant difference (p = 0.85) in diagnostic un-
derstanding ratings between PET scans indicating malignancy where the tumor was finally proven 
to be malignant (true positives) and scans indicating benign disease where the lesion proved to be 
benign (true negatives). To evaluate the presence of a potential clinical learning curve of incorpo-
rating PET scanning results, we compared the diagnostic understanding ratings of “early” patients 
(the first five patients) referred by a particular physician to the ratings of later patients (the sixth and 
subsequent patients). The ratings in later patients tended to be significantly higher (p = 0.0192).
Diagnostic accuracy
Of the patients referred to resolve unclear radiological findings, 76 patients had a positive PET scan 
result which proved to be true positive in 68 patients (89%). Thirty six patients had a negative scan 
reading –that is, no focally enhanced FDG uptake suspicious for malignancy–which proved to be 
correct (true negative) in 34 patients (94%) either by “wait and see” policy (n = 32) or surgery (n = 
2). The mean duration of follow up in these patients was 20 months (range 6-36). In two patients the 
PET scans proved to be false negative. These false negative cases included a patient with pulmonary 
fibrous tumor (the patient underwent a curative pneumonectomy) and a patient with mantle cell 
lymphoma (diagnosed 1 year after the PET scan). In one patient the indeterminate solitary pulmo-
nary nodule proved to be true positive at surgery but PET was found to have missed micrometastatic 
involvement of mediastinal lymph nodes.
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Of the patients referred for mediastinal staging, 24 patients had a positive PET scan result of which 
22 were proven to be true positive as shown by pathology in 16 patients and by follow up in six 
patients; one was proven to be false positive (as shown by pathology) and one patient was lost to 
follow up. Eleven patients had negative scan results which were found to be true negative in 10 pa-
tients (as shown by pathology in six patients and by follow up in four: mean time from PET to last 
chest radiograph or CT scan was 15 months, range 13-17). In one patient the PET scan was found 
to be false negative (as shown by pathology). In one patient the scan trajectory did not include the 
mediastinum due to claustrophobia. 
Of the patients referred because of distant staging issues, 10 were found to be true positive (as shown 
by pathology in six patients, follow up in two, and radiology in two). Six patients proved to have 
a true negative PET scan as shown by follow up in five patients (mean time of follow up 6 months, 
range 6-6). In one patient the PET result proved to be false negative (bone metastases). 




































Table 2. Treatment changes after PET (T = 4/5, n = 78)
Management changes
In 162 of the 164 cases studied explicit provisional therapeutic plans had been stated before PET. In 
103 patients this involved surgery. After PET, surgery was the treatment most commonly abandoned 
(table 2). PET contributed to a decision to forego surgical treatment in 36 patients (35%; 95% CI 
26 to 45) in whom it had been provisionally planned. Of the patients in whom surgery was not 
the proposed treatment before PET (n = 59), seven patients subsequently underwent surgery. In 
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patients, and radiotherapy in one patient. There was a significant change in terms of the “impact” of 
treatment for the patient, mainly toward a less aggressive approach (surgery→chemo-/radiotherapy→
observation; p = 0.0001). The impact of PET on treatment was divided into major or minor changes 
as outlined previously. PET was responsible for changes of choice of treatment that were major in 
55 patients (66%; 95% CI 55 to 76) and minor in 28 patients (34%; 95% CI 24 to 45). 
tC = 1 tC = 2 tC = 3 tC = 4 tC = 5 missing total
Radiological abnormality 1 16 42 21 30 2 112
Mediastinal staging 3 11 10 10 2 36
Distant staging 3 4 3 5 1 16
Overall 1 22 57 34 45 5 164
Table 3. The impact of PET on patient management and its clinical assessment (treatment choice (TC) ratings as 
defined in box 1
Post hoc evaluation of treatment choice 
The impact of PET on treatment choice was analyzed for each scan indication (table 3). According to 
the attending physician, PET was the most important factor leading to a beneficial change of treat-
ment (TC = 5) in 45 of 159 patients (28%; 95% CI 21 to 35) patients and contributed to such change 
(TC = 4) in 34 (21%; 95% CI 15 to 28). 
Of the 134 cases in which the physician reported increased diagnostic understanding, therapeutic 
plans remained unchanged in 59 cases (44%). No significant differences in changes of treatment 
choice for the three different indications were found (p = 0.65). Treatment choice ratings after PET 
scanning indicating malignancy when the suspected lesion was indeed found to be malignant were 
not different from scans indicating a benign lesion found to be benign (p = 0.27). Like diagnostic 
understanding, the treatment choice ratings were significantly higher for later patients than for early 
patients (p = 0.037). 
Discussion
A new test that appears to be more accurate than the standard ones will generate a clinical demand, 
even if it’s effect on clinical outcome measures is still unclear. With scarce technology like PET 
overconsumption may result precluding general accessibility. Evidence-based guidelines for routine 
use are therefore needed, so that the available scanning capacity can be adjusted to the expected 
demand. However, guidelines aim at the average patient and may not be applicable in specific situa-
tions. In this prospective, multicenter before-after study the reported clinical impact of 18FDG PET 
as an “add-on” technology to solve diagnostic problems in patients with suspected NSCLC was 
considerable. Clinical compliance with the PET results was high, and PET was reported to have 
led to beneficial management changes (TC≥4) in 50% of the patients in the three clinical situations 
26
investigated. In addition, a positive influence on diagnostic understanding (DU≥4) by PET was ob-
served in 84% of the patients. Put in a more conservative way, PET proved to be the key diagnostic 
tool in one of every four patients referred for PET (DU/TC = 5). 
Interestingly, we observed an increasing appreciation of PET over time. Even though other explana-
tions may also be valid, individual consultation and feedback as done in our setting, is known to 
improve patient referral patterns.14
Interpretation of the classification of “important contribution” to treatment choice by PET (TC 
= 4) is not straightforward. It is recognized that, in most clinical situations, decisions are made on 
the basis of a number of factors. Patient management depends on the preoperative assessment of 
the probability of disease, which is a joint function of multiple diagnostic indicators such as signs, 
symptoms and test results together with the effectiveness of the invasive procedures that follow 
them. This complicates the assessment of the contribution of a single test to a change in patient man-
agement. Even though the phrasing of the “contributive” ratings (DU/TC = 4) may benefit from 
accentuation, such positive perceptions may always contain a spectrum of clinical relevance which 
is difficult to translate into outcome measures. The assessment of the true value of “contributive” 
rather than directly decisive PET findings (TC = 4 v TC = 5) is therefore best done in a randomized 
study design. 
Some studies have recently addressed the clinical impact of PET. The methodologies and patient 
spectra were variable, but the reported management changes (65-70%)15-17 are uniformly higher 
than those observed as a by-product in accuracy studies (10-59%).18-19 This underlines the fact that 
management change is multifactorial and does not merely depend on a single test (such as PET). 
Alternatively, “clinical value” studies may have overestimated the true clinical contribution of PET. 
Firstly, the clinical impact of a new technology depends on the quality of the previous clinical work-
up; poorly performed conventional staging before PET scanning would overestimate its actual value. 
We therefore made an effort to restrict PET referrals to cases in which conventional investigations 
had indeed been performed and had failed. As we have shown, this was the case in the majority pa-
tients. Further, a retrospective analysis of the pre-PET work-up showed adherence to internationally 
accepted guidelines in the majority of patients. Secondly, whether a specific test contributed signifi-
cantly is a matter of judgment, and thus subject to disagreement, error and imprecise measurement.8 
This was, indeed, the case in our study; inconsistencies were identified in 18% of the questionnaire 
responses. To strengthen the evidence of before-after studies, independent reviewing of the data by 
experts has been suggested. This has been shown to reduce the presumed benefit of a new technol-
ogy as assessed with this type of study design.20 However, such findings may also reflect the hetero-
geneity of daily clinical practice in which patients are actually diagnosed and treated. Thirdly, un-
conscious bias of the referring clinicians in favor of the new technology may have affected the results. 
We cannot rule out that this has occurred but the opposite may also be true. Even though the sample 
was not randomly chosen, we found no such effect in the medical records of the cases in which a 
prolonged follow up was needed and the data were derived from a broad spectrum of hospitals. 
  The questionnaires used do confirm a distinction between the clinical impact of a test on diagnostic 
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of these changes. The data clearly show that the perceived benefit of PET scanning consists of altered 
patient management but, to an even greater extent, of increased diagnostic understanding or confi-
dence in cases where patient management was not altered. In their present form, the questionnaires 
do not allow estimation of the amount of clinical uncertainty. In our opinion, studies such as this 
may serve to estimate the relative merits of PET for different indications within a specific clinical 
context. If PET fails to show clinical impact, the presumed indication for PET may be removed 
from the list, whereas promising results warrant further investigation. Our data do not represent 
consecutive patients presenting with a similar clinical problem, and as such, our results cannot be 
extrapolated to imply the routine use of PET in all patients with suspected NSCLC. Estimation of 
the cost-benefit of such an application requires a direct comparison between patients subjected to 
PET and conventional work-up. Such a study is currently ongoing in the Netherlands.
In summary, controlled implementation of PET, as a ‘last resort’ diagnostic modality, improved pa-
tient management in at least 25% of clinically problematic cases with suspected NSCLC. The com-
bination of preliminary guidelines, intensive feedback, and prospective monitoring may promote 
the effective use of scarce technology. 
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To evaluate the impact of a new diagnostic imaging device on patient outcome, a randomized 
controlled trial (D-RCT) is considered to provide the best evidence. We reviewed the litera-
ture for D-RCTs, for time trends and study characteristics, applying a taxonomy accounting for 
main contrasts and outcome measures. 
study design and methods
Using Pubmed, a search on general D-RCTs included three distinctive years of publication, 
between 1990 and 2002. Another search focused on D-RCTs between 1990 and 2005 in which 
Magnetic Resonance Imaging (MRI) played a major role in the comparison.
results
The majority of studies pertained to testing different tracers or acquisition parameters with one 
particular device. An increase over time was observed in studies comparing devices over studies 
testing tracers. Only 15 D-RCTs were identified in which patient outcomes were studied.
The search on MRI revealed 13 D-RCTs of which 8 were published after 2000. In three studies, 
two devices were tested in the same patient, while in the others patients were randomly allo-
cated to one of two strategies. 
Conclusion
Although generally advocated, randomized controlled trials in diagnostic imaging are not fre-
quently performed. As a consequence, evidence on (cost)-effective use of imaging tests is lack-
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introduction
In general, establishing effectiveness of diagnostic imaging devices has two components: [1] estab-
lishing the accuracy of the test and [2] establishing its clinical value. In the ideal world, an image is 
pathognomonic for a specific diagnosis, and patient management follows from this diagnosis. In the 
reality of imaging, there are “gray areas”, doubts, conjectures.3 This is especially pressing in settings 
where tests are used sequentially (e.g. to stage a cancer patient) followed by invasive procedures with 
variable yield. The use of diagnostic devices without defined benefits may cause harm to patients, in-
cluding [1] further unnecessary diagnostic testing, including invasive processes [2] directing patients 
to inappropriate therapy, and [3] creating unwarranted patient anxiety from abnormal test results. 
An application for marketing authorization for a diagnostic agent/test4 should therefore address 
both accuracy and clinical value as proposed by Fryback and others in a hierarchical framework.5 
In this often cited hierarchical framework, the three last steps support the clinical efficacy: patient 
management efficacy, patient outcome efficacy and societal efficacy. Especially for the impact on 
patient outcome, a randomized controlled trial (RCT) is usually considered to provide the best 
evidence, just like in medical intervention research.5-8 
In 1996 we were asked to plan a study assessing the cost-effectiveness of PET in NSCLC. Because we 
considered a RCTs to be the optimal in this situation, we performed a literature search for random-
ized diagnostic imaging studies, to help and design the study. We identified many papers applying 
randomization, but very few appeared to address patient outcomes as a function of the applied diag-
nostic test(s) which was in fact our main research question. In 2005 we updated the literature search 
with another 10 years.
The aim of the present work was first to design and apply a taxonomy of diagnostic RCT’s (D-RCT’s) 
accounting for main study contrasts and outcome measures, and second to investigate trends in time 




Two complementary searches in MEDLINE® were performed. Both search strategies included terms 
suggestive of randomized controlled trials as proposed by Dickersin.9 The set of keywords were op-
timized interactively with experience from known diagnostic studies and by investigating the results. 
We included studies on patients referred for diagnostic work-up for some suspected state of disease 
or for a condition that required medical intervention. Screening trials, where the issue was to screen 
or not to screen in ‘non-diseased’ populations were therefore excluded. 
The abstracts of all identified articles were reviewed initially by one author (HvT), and classified 
according to the research topic and the design. When abstracts were not sufficiently informative, 
full papers were collected. Of all relevant abstracts, full articles were gathered for further review. No 
formal systematic complementary hand-search procedures were applied. 
Our first search included three distinctive years of publication at intervals of 6 years to be able to 
capture possible developments in time: 1990, 1996, which was the year just before we actually de-
signed our first D-RCT to study the role of FDG-PET in NSCLC10 and 2002, the year of its pub-
lication.11 
In a second approach we focused on D-RCTs in which Magnetic Resonance Imaging (MRI) played 
a major role in the comparison. MRI is the most recent tomographic imaging device before PET and 
may bear many similarities in terms of introduction into clinical practice. Moreover, by limiting the 
search in terms of a particular device it was feasible to include a longer time range as to study pos-
sible time trends. Randomized Controlled Trials and Magnetic Resonance Imaging were included 
as MESH terms together with a time range from January 1990 until October 2005 (Table 1b). Again, 
mass screening was excluded. 
Taxonomy
We designed a taxonomy based on a classification of the main study contrast as well as the outcome 
measures (Table 2). The classification of endpoints was derived from the hierarchical model of Fry-
back.5 In this model, the first level is concerned with technical efficacy, including technical aspects 
of the image and safety aspects of the imaging contrast agent or radiopharmaceutical. The second 
level involves the diagnostic accuracy, often expressed in measures of sensitivity and specificity. In 
this study, the third and fourth level, associated respectively with diagnostic thinking (impact) and 
therapeutic impact were taken together because they are usually studied together in each other’s 
extension in a particular study design. The fifth level concerns the patient outcome efficacy and a 
sixth level is addressed if costs and benefits from a societal viewpoint are included. For each study, 
the highest level of endpoint reported was assigned although parameters of previous levels were 
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We extracted a set of predefined parameters of individual studies: the contrast, defined as the actual 
comparison studied, endpoints, disease type, patient spectrum and the timing of randomization, 
e.g. before or after the use of the device or tracer. This accounts for the issue whether patients were 
randomized to a particular device or whether scans were randomized among observers. Finally, we 
extracted population characteristics and logistical aspects to assess the external validity, such as the 
number of patients and whether the study was mono- or multicentric.
(((“Diagnostic Imaging”[MAJR] OR “Signs and Symptoms/radiography”[MAJR]) OR “Signs and 
Symptoms/radionuclide imaging”[MAJR]) OR “Signs and Symptoms/ultrasonography”[MAJR]) AND 
((((“clinical trials”[Mesh:noexp] AND (((randomized[tiab] OR randomised[tiab]) OR control[ti]) OR 
controlled[tiab])) OR (“controlled clinical trials”[mesh] AND (randomized[tiab] OR randomised[tiab]))) 
OR “Randomized Controlled Trial”[Publication Type]) OR (“Controlled Clinical Trial”[Publication Type] 
AND (randomised[tiab] OR randomized[tiab])))
Table 1a. Medline search 1 (see text)
“Magnetic Resonance Imaging”[MAJR]AND (“randomized controlled trial”[Publication Type] OR 
“randomized controlled trials”[MESH Terms]) AND (“1990/01/01”[PDAT] : “2005/10/31”[PDAT])
Table 1b. Medline search 2 (see text)
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results
The initial search (Table 1a) revealed 66, 194 and 243 potential titles in 1990, 1996 and 2002. Of 
these, respectively 30 (45%), 70 (36%) and 50 studies (21%) were eligible because they used a design 
that involved some type of randomization of the diagnostic technique or an aspect related to diag-
nosis. In 27 studies diagnostic devices or strategies were compared (table 2, categories I, II), while the 
majority of studies (82%) pertained to testing different tracers or acquisition parameters with one 
particular device (table 2, III-VII). A substantial increase over time was observed in the number of 
studies comparing devices in contrast to studies testing tracers (table 2). 
Table 2. D-RCT’s categorized by type of contrast by year of publication
Fourteen studies contrasted one device directly against another (table 2, I). We were able to distin-
guish different types of designs. For example, in some studies two devices were applied and compared 
within the same patient. Randomization either served to account for disease progression between 
tests (randomization of the order in which the tests were performed) or to reduce case and observer 
bias if added value of tests was at stake (randomization of the order in which test results were offered 
to observers). An example of the first situation is the comparison of diffusion-weighted MRI with 
CT in hyperacute stroke patients.12 The second situation was found in a study on the follow-up of 
patients surviving aortic dissection, where transesophageal echocardiography was contrasted to X-
ray computed tomography.13 There, the additive value of one test over the other was studied in the 




n (%) n (%) n (%) n (%)
Contrast
. . 6 (8.6) 8 (16.0) 14 (9.3)
I Imaging Device A versus B
II Imaging Device A versus no A 3 (10.0) 1 (1.4) 9 (18.0) 13 (8.7)
III Different acquisition parameters, single device 2 (6.7) 13 (18.6) 12 (24.0) 27 (18.0)
IV Tracer A versus B 16 (53.3) 25 (35.7) 4 (8.0) 45 (30.0)
V Tracer A: different concentrations 2 (6.7) 5 (7.1) 7 (14.0) 14 (9.3)
VI Different disease status,  single device . . 1 (1.4) . . 1 (0.7)
VII Devices or interventions supporting the imaging 7 (23.3) 19 (27.1) 10 (20.0) 36 (24.0)
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der was not important, and only the scans were randomized and interpreted retrospectively by two 
observers. This situation was found in a study in patients with anterior mediastinal masses where 
the objective was to compare chest radiography with computed tomography in the prediction of a 
specific diagnosis.14 Overall, such type of design, where randomization referred to the ‘shuffling’ of 
images after scanning and before interpretation by (blinded) reviewers, was applied in eleven out 
of 150 identified randomized studies. In only two of the 14 studies within the category of device 
comparisons (Table 2, I), patient outcomes were part of the endpoint of investigation.  One looked 
at the value of computer-aided diagnosis versus contrast radiography on morbidity and mortality of 
patients with acute small bowel obstruction15 and another at the impact of MRI versus plain radio-
graphs for low back pain on patient outcomes.16 
In 13 studies patients were randomized to a (conventional) diagnostic strategy or to the same strat-
egy with a new test on top of it (table 2, II). All focused on an endpoint beyond accuracy. The 
spectrum of diseases studied included cancer, cardiovascular- and musculoskeletal problems (e.g. 
low back pain). Sample sizes ranged from 15 patients in a study to validate MRI versus radio-opaque 
markers for diagnosis of delayed gastric emptying in diabetic patients, to 2475 in a trial comparing 
a conventional strategy in emergency department patients versus the usual strategy supplemented 
with results from acute resting myocardial perfusion imaging using single-photon emission com-
puted tomography. 
The largest group of studies (table 2, IV,V) used randomization for comparison of different imaging 
agents (radiological contrast agents or radiopharmaceuticals) using the same scanner (49%). The 
number of such studies decreased over time representing 60% of all eligible studies in 1990, 43% in 
1996 and 22% in 2002 (table 2, IV). Studies investigating devices and interventions supporting the 
imaging process, (eg. standard versus pediatric probes for transesophageal echocardiography, or dif-
ferent sedatives) were also frequently reported and their number was stable over time (table 2, VII). 
For the category of testing different agents or acquisition parameters with one particular test device, 
typically the objectives or endpoints are related to diagnostic accuracy and/or technical efficacy 
including safety parameters and sometimes to associated costs (table 3). In the case of supportive 
interventions, comforting the situation of the patient and improving patient recovery (patient out-
come or costs) were considered relevant endpoints, but with little relevance to the potential of the 
diagnostic device itself. Therefore within this taxonomy, the endpoints were graded as technical or 
improving diagnostic efficacy at most.
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MRI-studies 
Of the initially identified 503 MRI papers, about one-third (156) reported the results of an actual 
RCT, focusing on an aspect of diagnosis. Of these 156 studies, the majority (76%) pertained to the 
analysis of different acquisition parameters (fast-spin echo versus conventional spin echo sequences, 
or imaging at 0.5T versus 1.5T) or contrast agents in a particular setting. Contrast agents or more 
frequently, their optimal concentration were investigated in 77 studies (49%). In 9 studies, MRI’s 
were made both in patients known to have a specific disease and controls known to be without that 
disease. An example of such a study was a trial where MR studies were performed in 100 subjects 
with clinical histories of stroke and 203 subjects without reported histories of stroke. MR scans were 
independently evaluated by two trained neuroradiologists for the presence of small (≤ 3 mm) and 
large (> 3 mm) ‘infarctlike’ lesions.17 Here, randomization pertained to the random distribution of 
images among multiple observers (see before (14)). In fourteen studies (9%), tools or agents (seda-















n n n n n n
Contrast
3 5 4 2 . 14Imaging Device A versus B
Imaging Device A versus no A . 1 1 7 4 13
Different acquisition parameters, 
single device 7 19 1 . 27
Tracer A versus B 22 21 2 . . 45
Tracer A: diff concentrations 8 6 . . . 14
Different disease status, single 
device 1 1
Devices or interventions 
supporting the imaging 32 4 36
All 75 60 6 14 4 150






















device A vs B 0 16 3 2 3 24
device A vs no A 1 2 2 4 4 13
Different acquisition parameters,  
single device 8 11 . 0 0 19
Tracer A vs B 10 18 . 0 0 28
Tracer A: different concentrations 21 17 . 0 0 38
Tracer A versus no A 5 6 . 0 0 11
Different disease status, single 
device 4 5 . 0 0 9
Devices or interventions  
supporting the imaging 13 1 . 0 0 14
Total 62 76 5 6 7 156
Table 4. 
Eighteen publications were found that involved a comparison of MRI to alternative test(s) using 
endpoints beyond diagnostic accuracy. However, a more detailed analysis revealed that only 13 
were unique D-RCT’s and 5 other manuscripts referred to interim analyses or derived subgroups 
(Table 5a and b). In 10 of 13 D-RCT’s, patients were randomly allocated either to a diagnostic pro-
cess including MRI or to a device or diagnostic process without MRI. In the three remaining studies, 
patients underwent MRI as well as the competitive procedure, and the results were then random-
ized for use in diagnostic and therapeutic decisions. Musculoskeletal diseases were studied most 
frequently. Other individual studies involved recurrent breast cancer, gallstone pancreatitis, periph-
eral arteries, guidance of stereotactic procedures in Parkinson’s disease and the decision to perform 
caesarean delivery with breech presentation at term. Usually, MRI was contrasted to a procedure 
without MRI on top of a conventional policy. One study investigated early imaging versus a policy 
without immediate imaging, where the choice of the imaging device, either CT or MRI, was left to 
the investigator.18 
Major endpoints of the 13 studies are also reported in table 5a and b. Diagnostic and therapeutic 
impact was usually measured in terms of the need for and number of additional tests. Quality of life, 
QALY’s and number of days immobilized were parameters of patient outcome. No study considered 
survival as major endpoint. Six of these 13 studies accrued less than 100 patients, five between 100 
and 500 patients and two accrued 500 and 782 patients, respectively. No exceptional difficulties in 
patient accrual were reported. Of the 13 studies, 4 were published in 2005, 4 between 2000 and 2005 
and 5 between 1990 and 2000. 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Imaging tests are not introduced through carefully planned prospective evaluation of diagnostic and 
therapeutic impact and (cost)-effectiveness. In other words, the generally appreciated and advocated 
hierarchical framework of test evaluation is rarely fully applied to diagnostic imaging tests. This 
finding is in agreement with an analysis of diagnostic and screening radiology outcomes literature 
from 1990. Out of 4,205 articles potentially describing radiology outcomes investigations only 40 
randomized controlled trials were found.19 Also, a recent search in the Cochrane Central Register 
of Controlled Trials (issue 1, 2005) showed that only 4.2% of the records dealt with diagnostic tests 
or screening.20 Our primary aim was to focus on studies where patients would be prospectively ran-
domized to undergo some diagnostic test. Randomization is primarily used to balance known (and 
unknown) prognostic factors to prevent confounding the relation between intervention and out-
come. If that is accomplished, the result of the imaging procedure is the only variable between the 
study groups.21 In our search the randomization-label was often ‘misused’ to indicate a procedure 
of shuffling of images retrospectively obtained in order to distribute them ‘randomly’ to observers. 
Here, randomization is merely used to blind observers for any systematic order in the images. Obvi-
ously, such a design is unsuitable for studying patient outcomes.
Our general search for D-RCT’s revealed 19 trials studying patient management, patient outcome or 
societal efficacies of imaging tests in 3 different years. No particular device or disease dominated. The 
search for studies randomizing patients to MRI versus another device or process revealed 13 primary 
studies in the past 15 years. 
Remarkably, randomization seems to be totally accepted in the studies of different contrast agents 
or different concentrations of the same agent. In 1996 even a meta-analysis of 57 randomized dou-
ble-blind clinical trials of one of the agents was published.22 Paradoxically, randomization also ap-
pears to be an accepted and commonly used tool in screening trials (which often include the use of 
imaging test). Screening trials deal with the highest level of patient outcome (cost-effectiveness of 
screening versus no screening). In the earlier cited synopsis on radiology outcomes literature, the 40 
randomized trials included 8 breast screening trials and 4 in lung cancer.19 A possible explanation 
could be the fact that screening trials are no more the domain of a single center, but can only be suc-
cessful in large areas and require the involvement of many more disciplines including methodolo-
gists, economists and health technology assessors. 
In accordance to our first conclusion, we noted a lack of literature search strategies to identify RCT’s 
on diagnostic tests as opposed to the situation with accuracy studies. In recent years several groups 
spent a credible effort in developing search strategies for diagnostic research and articles related to 
clinical guidelines and the appropriateness, process, outcome, cost and economics of health ser-
vices.23-27 Most of these search strategies aim to find diagnostic accuracy studies and include search 
terms like sensitivity and specificity. Nowadays, dedicated algorithms are available in Pubmed to fa-
cilitate the literature search.23 This algorithm however, was not useful to identify diagnostic studies 






ized controlled trials: a review
The number of relevant studies detected by our first search is so low that it does not allow finding 
patterns or methods related to a type of diagnostic device or to a particular disease indication. How-
ever, over the three years, an increase in the number of relevant studies was observed. 
Because we were primarily interested in outcome studies (both patient outcome and costs) related to 
a new diagnostic imaging device, bearing similarities to PET, we focused on studies investigating the 
role of MRI in the last decades. The MRI experience suggests that, more recently, individual centers 
set out to perform such RCT’s but it is certainly not a widely accepted approach.28 The majority of 
studies dealt with musculoskeletal problems or arterial disease and were mainly coming from spe-
cific groups from the UK18,29-32 or the Netherlands.33,34 Endpoints included the need for additional 
imaging or surgical procedures to quality of life and ultimately cost. All studies focused on the ben-
efit of entire diagnostic strategies, one of them including MRI, rather than the assessment of MRI as 
a single test. In three studies, the conventional and the experimental devices were applied both in all 
patients. When the availability is not a concern and no particular risk is involved with the new de-
vice, this design may have the advantage of obtaining information with the technique in all patients. 
Often however, applying the new device is costly and the technique may not be sufficiently available 
for a new indication. In our experience, medical ethics committees dislike designs where all patients 
are exposed to an experimental device without using the information for clinical decision making. 
Our search did not reveal any study in which patients were randomized to further testing or therapy 
on the basis of a test result. Such a design has been suggested to gain efficiency when the efficacy of 
the therapy or management following the test is uncertain.8 Moreover, further management was 
only specified in 3 out of the 13 randomized MRI studies. Running trials without a protocol translat-
ing the test results to clinical management decisions has been criticized because of the fact that too 
many variables are at stake. Differences might be due to the test, management decisions guided by 
those tests or low effectiveness of subsequent treatment.  The choice of the endpoint of diagnostic 
trials in this respect is very important and should be as close and relevantly linked to what may be 
expected as a result of the test. 
None of the studies mentioned particular difficulties in ethical issues or accrual of patients. Most of 
the studies had an enrollment period of less than 3 years, which is totally acceptable and very similar 
to the situation in medicine trials. However, most trials were rather small, certainly compared to 
what is usually required to reliably assess the efficacy of new drugs. In general the papers lacked a 
proper justification of the sample size.
In conclusion, there seems to be a serious discrepancy between the often advocated principles for 
evaluation of new diagnostic technologies and devices and the methods that are actually applied in 
studies. As a consequence, evidence on (cost)-effective use of imaging tests is lacking in general. The 
experience with MR, corroborated by our own experience,11,35 although limited to a few situations 
and centers, shows that they are feasible and recently more often performed. 
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Abstract
Non-small cell lung cancer can be cured if the patient is medically operable and the tumor 
resectable. Current diagnostic strategies are aimed to detect tumor deposits that preclude 
resection with curative intent. However, these strategies are rather inefficient, resulting in a 
large number of futile invasive procedures. In the early 1990s positron emission tomography. 
PET; showed promising results at its introduction in the clinic, especially in oncology.  
A large number of accuracy studies have reported that PET is superior to conventional imaging. 
However, whether PET ultimately improves patient outcome should ideally be assessed by 
means of a randomized controlled trial. No such design has been applied to evaluate PET in 
oncology so far. The PLUS study was designed to compare the current strategy of conventional 
methods with a strategy where PET was added after completion of noninvasive techniques. 
Patients considered operable by the physician at this point were then randomly assigned to 
PET and further consequences or to standard procedures of mediastinoscopy or thoracotomy. 
Primary outcome events were futile thoracotomies. The trial randomized 188 patients from 







A patient with non-small cell lung cancer. NSCLC; can be cured only if the patient is medically 
operable and the tumor resectable. The clinical diagnostic workup of such patients aims to 
establish a diagnosis of NSCLC. the primary tumor; preoperatively and to identify lymphatic or 
hematogeneous metastases to restrict curative surgery to patients who potentially benefit from this 
treatment. For this purpose, a battery of diagnostic tests examining the various target tissues [lymph 
nodes with chest computed tomography. CT; scan, bone with plain X-rays, skeletal scintigraphy, 
brain with CT/magnetic resonance imaging. MRI;; liver and adrenals with CT or ultrasound] 
are at the clinician’s disposal. Various guidelines have been formulated to optimize these efforts.1-4 
In daily clinical practice, however, variation is considerable.5-8 In some hospitals, patients without 
enlarged mediastinal lymph nodes. MLN; at CT scanning proceed directly to thoracotomy. In other 
hospitals, mediastinoscopy is part of the standard workup. Mediastinoscopy is always performed in 
patients with enlarged N2 MLN. Sensitivity and specificity of CT in detecting mediastinal nodes 
are, respectively, 52% and 69% so that patients with negative CT who proceed to thoracotomy may 
in fact have N2 MLN disease9. Mediastinoscopy itself may also be inaccurate. Thus, the prevailing 
diagnostic strategy leads to futile thoracotomies in up to 50% of patients.8,10,11 
In the early 1990s positron emission tomography. PET; emerged as a promising diagnostic imaging 
tool in nuclear medicine. In the oncological setting, the combination of whole-body PET with the 
tumor-seeking radioactive tracer fluorodeoxyglucose. 18FDG; allows for noninvasive visualization 
and quantification of tumor deposits. Since PET provides spatial and metabolic information, it can 
assume a complementary role to currently available morphological imaging, or even surpass these 
techniques. A large number of published accuracy studies have reported, without exception, that PET 
is superior to the CT scan in assessing the nodal, i.e., mediastinal tumor status.12 However, accuracy 
studies are not only highly susceptible to bias, but also fail to cope with the full complexities of how 
an imaging technique contributes to the diagnostic and therapeutic process.13-17 By definition, the 
design requires that the technique be assessed out of the clinical context.18 More accurate staging may 
lead to more appropriate treatment planning, but prospective evidence for that is largely anecdotal.19 
Such evidence is subsequently used in decision analyses, where risks, benefits, and costs of various 
strategies are modeled mathematically.20 Several of these studies suggest that PET is cost-effective 
in NSCLC staging.21,22 Given these limitations, ideally a randomized controlled trial. RCT; should 
assess whether PET provides information that ultimately improves patient outcome.18,20,23 
Where patients are selected for curative surgery, the achievable health gain consists of a reduction 
of the number of futile surgical procedures. The PLUS study. PET in LUng cancer Staging; was 
designed to compare the current strategy of conventional methods with a strategy where PET was 
added to the noninvasive techniques with respect to these outcomes. Since the introduction of 
new health technology for specific clinical indications requires not only justification in terms of 




Eight community hospitals and one academic hospital recruited patients for the trial. Patients with 
suspected or proven NSCLC, considered medically operable and potentially resectable by the 
local pulmonary physician on the basis of clinical staging procedures. i.e., clinical stage I-III;, but 
prior to surgical staging, were invited to participate. see Figure 1;. The diagnostic routine in each 
hospital was respected. Inclusion and exclusion criteria were minimal to guarantee fast accrual and 
generalizability. No particular adverse events were expected. Patients had to be older than 18 years 
of age and comply with written informed consent according to local medical ethical committee 
regulations. 
In exactly one calendar year 188 patients were randomized. The results are presented in Chapter 5. 
surgical candidate
NSCLC ? → after conventional 
non-invasive work-up
Conventional
Invasive staging & surgery
Pet → conventional
Verification/ invasive staging & surgery
r
Figure 1. Trial design of PLUS study. Note that patients had to be older than 18 years and comply with written 
informed consent. All procedures other than PET, including therapy and follow-up, were performed by the referring 
institute (nine hospitals) according to prevailing local standards 
Diagnostic outcome Suggested implication
CT normal and PET normal: Exploratory surgery with curative intent
CT abnormal and PET normal:
 – Central tumor and adjacent lymphadenopathy
 – All other cases
Mediastinoscopy
Surgery with curative intent 
CT normal and PET abnormal: PET guided biopsy (usually mediastinoscopy)
CT abnormal and  PET abnormal: PET guided biopsy (usually mediastinoscopy)







To randomize a patient, the pulmonary physicians called the central data center. After verifying 
eligibility criteria, patients were randomized by computer according to a permuted block design 
stratified for local institute. Patients were allocated either to PET scanning or to further invasive 
diagnostic or treatment-related procedures as dictated by local routine. 
PET Procedures
PET scans were performed at the PET center of the academic hospital Vrije Universiteit in Amsterdam. 
The participating hospitals were located within 50 kilometers of this center. For the purpose of the 
study, the PET center guaranteed a PET scan within 2 days after randomization. The chest CT 
san was available for reading.24 Patients had to fast for 6 hours prior to scanning. Serum glucose 
was measured in a blood sample drawn from an intravenous cannula that also served to inject the 
radioactive tracer. The PET scanner was a Siemens ECAT EXACT HR+. The 1-hour whole-body 
acquisition started 1 hour after injection of 370 MBq 18FDG and the scanned trajectory included 
skull to midfemur. PET images. non-attenuation-corrected emission scans; and their interpretation 
were communicated to the referring physician by telephone and confirmed in writing. 
PET Evaluation and Implication
Two readers of a group of three assessed all PET-scans; if necessary, consensus was reached with a 
third reader. Scoring of pulmonary and mediastinal lesions was visually related to the mediastinal 
background activity, using a three-point scale: 0 = activity less than background, 1 = activity equal to 
background, 2 = activity clearly above background. Transmission-emission overlays served to define 
the nodal status of the focal activity.25 The first reading was blinded for CT. Focal activity outside 
the mediastinal area was reported on a five-point scale as normal/definitely benign, probably benign, 
equivocal, probably malignant, or malignant. The report of the PET scan contained information 
on the nature of the primary lesion, on lymph node status and distant metastases; it concluded 
with an assessment of TNM stage and advice for further workup in which the results of previous 
CT scanning were incorporated. see Table 1;. The following guideline was proposed: specimen 
verification of clinically relevant distant or nodal FDG foci, targeting lesion. s; with decisive impact 
for patient management that were the most easily accessible. Often this would imply verification of 
distant sites. If unconfirmed, the patient received the benefit of the doubt, and the PET findings were 
ignored. The attending clinicians were free to use the information and to act upon it. For patients 
without evidence of hematogeneous or extrathoracic lymphatic metastases the general approach 
described in Table 1 was proposed for evaluation of the mediastinum.21,24 
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Follow-up
All diagnostic procedures other than PET, the actual therapy as well as the clinical follow-up, took 
place in the referring hospital according to local standards, which consisted of regular visits. every 
2-3 months; in the outpatient clinic. Follow-up information was collected 6 and 12 months after 
randomization. Trained data managers visited each hospital regularly and collected all data. 
Outcome Events
The primary endpoint was the difference in the number of futile thoracotomies between the 
conventional arm and the PET-including arm. Thoracotomy was classified as futile in the case of 
benign lesions, pathologically proven mediastinal lymph node involvement. stage IIIA-N2;, stage 
IIIB, explorative thoracotomy for any other reason, or recurrent disease or death of any cause within 
1 year after randomization. Thoracotomy was not considered futile in case of minimal N2-disease. 
i.e., intranodal involvement in a single lymph node at mediastinal dissection;. Secondary endpoints 
were morbidity, complications, and cost and duration of diagnostic and therapeutic processes. 
Statistics
Before the trial was designed, current clinical practice was assessed in a retrospective analysis of 
staging procedures and their results in all patients evaluated for proven or suspected NSCLC in the 
two largest participating centers. Vrije Universiteit and the Medical Center Alkmaar, a community 
hospital.8 Based on these results and the international PET literature, it was estimated that the 
use of PET imaging might reduce the number of futile thoracotomies from 45% to 20%, which 
corresponds to an absolute reduction of 25%. This reduction is based on the more conservative 
number of reduction of both hospitals. To reliably detect a reduction of 25%. power of 90%, alpha 
of 0.05 two-sided;, 80 evaluable patients in each arm were required. However, the potential number 
of patients expected from the centers in combination with the nature of the experimental technique 
in terms of burden to patients or physicians would allow a larger number of patients to be accrued in 
the trial. Therefore, the trial was open for an accrual period of 1 year, with a minimum of 160 patients. 
The number of futile surgical procedures in both arms will be simply expressed as a binomial value 
and can be tested using a Chi-square test. Logistic regression will allow the inclusion of certain 
potentially confounding variables, such as age of the patient and clinical stage at presentation, into 
the analyses. Using the definition for failures as described earlier. at surgery and 12-month follow-up;, 
sensitivity, specificity, accuracy, and predictive values will be calculated. Because of the expected low 
risk of PET imaging and the relative short accrual time, no interim statistical analysis was planned. 
Cost Analysis
Data on direct medical costs of diagnosing patients. including thoracotomy; and costs due to related 
complications are concurrently collected for both randomization arms. Total costs, based on volume 
multiplied by full costs, will be calculated and compared. If PET proves to be clinically effective, 
sensitivity analyses based on accuracy measures provided by this study, together with information 







Before investigators were allowed to randomize patients they were invited to refer at least three 
patients to the PET center to get acquainted with the routing and the implications of the PET 
scanning procedure. Meanwhile, approval of the medical ethical committee of the institute was 
requested. During the trial, meetings were organized every 2 months for all participants. pulmonary 
physicians, surgeons, radiologists; to discuss experiences and the progress of the trial. After each 
meeting a newsletter was sent to all study collaborators. 
Discussion
The introduction of new health technology requires justification of cost-effectiveness for specific 
clinical indications. In the case of a diagnostic imaging technique, effectiveness means that it not 
only provides more accurate data than existing modalities, but also improves patient management 
and ultimately has a favorable impact on health status at reasonable costs. In the development 
of new therapeutic agents, acceptance and reimbursement can only be achieved by at least two 
randomized studies showing their benefit. This is in sharp contrast with the evaluation of diagnostic 
tests, where RCTs are extremely rare. Here, acceptance of technology seems to grow along a steadily 
increasing number of published accuracy studies for a certain indication. As a consequence, new 
and expensive but not optimally effective techniques often diffuse into clinical practice, potentially 
slowing down innovations in other areas.26,27 Apart from the fact that accuracy studies are often of 
poor quality, their products, i.e., sensitivity and specificity estimates, are only indicative and of little 
relevance to the actual effectiveness of a test.13-17,28,29 A useful test should also have diagnostic and 
therapeutic impact: the test should add information relevant to what was already known, and the 
surplus of information should contribute to therapy decisions.14,30 Finally, even if all of these levels 
can be evaluated positively, the question whether the use of the technique actually contributes to the 
health of a patient is still unanswered. Our definition of futile thoracotomies as operationalization 
of health outcome of PET scanning in potentially resectable NSCLC is based on consensus of 
prevailing surgical management of NSCLC in the Netherlands and is supported by international 
guidelines.1-3 Noncurative surgery unnecessarily increases the burden of disease and risk in many 
patients. In addition to surgery-related risks, life expectancy may improve if patients with locally 
advanced NSCLC have the opportunity to receive preoperative or neoadjuvant strategies including 
chemotherapy or chemoradiation.31 We discussed including quality of life as an outcome in the trial. 
However, this important outcome is probably influenced by many factors outside the scope of the 
study. For example, it is not unlikely that quality of life would improve in the immediate aftermath 
of futile surgery, at least until it became obvious that the procedure failed to cure the disease. And 
even on failure the patient might continue to believe “that at least everything possible was done.” In 
contrast, a patient spared futile surgery by PET would immediately experience the loss of quality 
associated with the verdict that cure was no longer possible or highly unlikely. Thus we felt quality 
of life was not useful as an outcome measure to test the efficacy of PET. 
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We suggest our design, i.e., a trial that randomly allocates patients to either conventional diagnostic 
workup or similar workup supplemented with the new technique, may be optimal to answer 
this question. The major benefit of randomization in a diagnostic process is that at any moment 
all available information on a particular patient can be used and that the randomized groups are 
similar with respect to all known and unknown factors, thus permitting an unbiased comparison. 
It is difficult to reason why these designs are applied so rarely in the evaluation of diagnostic 
techniques. Obviously, a complexity of forces are involved in the assessment and diffusion of new 
technologies.32 “Publishing early and often by academics fortunate enough to gain early access to 
new technology has been rewarded with accelerated promotion and tenure, recognition within the 
diagnostic community, and often, favorable financial arrangements with manufactures eager to align 
themselves with well-known scientists”.33 Because of this uncritically low level of acceptance of new 
technologies, the time window in which investigators consider it ethical to randomize patients is 
extremely short.34 Medical ethical committees, policy makers, and patient movements might also 
put pressure on this window of opportunity.31,35 For the present study, patient enrollment was 
finished within 1 year. Data from the Netherlands Cancer Registry36 indicate that the present study 
included approximately 65% of all eligible patients diagnosed in the nine participating centers. In the 
Netherlands, PET is not yet commonly available for routine diagnostic investigations. PET capacity 
is still limited to three scanners per 15 million inhabitants. Because of this shortage of availability, 
the ethics of this trial are justified, as was the case in the pioneering MRC trial of streptomycin for 
tuberculoses.37 Hopefully, this trial is still timely and may help the clinical community in defining 
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Up to 50% of curative surgery for suspected non-small-cell lung cancer is unsuccessful. Accura-
cy of positron emission tomography (PET) with 18-fluorodeoxyglucose (18FDG) is thought to 
be better than conventional staging for diagnosis of this malignancy. Up to now however, there 
has been no evidence that PET leads to improved management of patients in routine clinical 
practice. We did a randomised controlled trial in patients with suspected non-small-cell lung 
cancer, who were scheduled for surgery after conventional workup, to test whether PET with 
18FDG reduces number of futile thoracotomies.
methods
Before surgery (mediastinoscopy or thoracotomy), 188 patients from nine hospitals were ran-
domly assigned to either conventional workup (CWU) or conventional workup and PET 
(CWU+PET). Patients were followed up for 1 year. Thoracotomy was regarded as futile if the 
patient had benign disease, explorative thoracotomy, pathological stage IIIA-N2/IIIB, or post-
operative relapse or death within 12 months of randomisation. The primary outcome measure 
was futile thoracotomy. Analysis was by intention to treat.
findings 
96 patients were randomly assigned CWU and 92 CWU+PET. Two patients in the CWU+PET 
group did not undergo PET. 18 patients in the CWU group and 32 in the CWU+PET group 
did not have thoracotomy. In the CWU group, 39 (41%) patients had a futile thoracotomy, 
compared with 19 (21%) in the CWU+PET group (relative reduction 51%, 95% Cl 32-80%;  
p = 0·003).
interpretation 
Addition of PET to conventional workup prevented unnecessary surgery in one out of five pa-








Accurate staging of patients with a pulmonary lesion suspected of being non-small-cell lung cancer 
is needed to restrict surgical or multimodality treatment to those who will potentially benefit from 
these treatments. Several imaging techniques and invasive tests are available to the clinician to detect 
mediastinal lymph-node involvement, distant metastases, or both. International guidelines to make 
the most of this process1-4 have been formulated, but routine clinical practice remains variable.5-8 
Despite current diagnostic workup, early local and distant relapses are frequent, and surgery is done 
for preoperatively suspicious lesions that can prove to be benign. Therefore, surgery can be regarded 
as futile in up to 50% of patients with presumably resectable non-small-cell lung cancer.8-10
Positron emission tomography (PET) with the tracer 18-fluorodeoxyglucose (18FDG) has emerged 
in the past decade as a promising oncological imaging tool. Results of several accuracy studies have 
suggested that 18FDG-PET is better at assessment of suspicious lung lesions and nodal or extra-tho-
racic tumour status in non-small-cell lung cancer than conventional workup.11-14 Accuracy studies 
are, however, not designed to show added value of diagnostic tests. Like phase II studies for develop-
ment of treatments, they are subject to bias, which make generalisation of results to predict an effect 
in routine practice difficult.15 In general, these drawbacks lead to overestimation of worth.16 As a 
result, whether and to what extent patients will benefit from use of PET in a routine clinical setting 
cannot be directly inferred from existing published work.17,18
As in assessment of new treatments, new diagnostic technologies need to be compared with cur-
rent strategies with respect to relevant clinical outcomes.19-21 Workers on major health-technology 
assessment reports20,22 concluded that improvement of diagnostic accuracy by PET was difficult 
to quantify because of variable quality of studies, and that direct evidence on the effect of PET in 
improvement of patients’ outcomes was still lacking.
The PLUS (PET in LUng cancer Staging) study was designed to work with routine clinical workup 
of patients with suspected non-small-cell lung cancer. We compared the current strategy of con-
ventional diagnostic methods with a strategy in which PET was added to non-invasive diagnostic 




We invited patients with suspected or proven non-small-cell lung cancer that was judged to be 
medically operable and potentially resectable by the referring clinician on the basis of clinical stag-
ing—but not surgical staging—to participate in the study. Eligible patients had to be older than age 
18 years. All patients gave written informed consent in accordance with requirements set by local 
medical ethics committees. Eight community and one university hospital recruited patients for the 
study.
Procedures
We randomly assigned eligible patients either PET followed by further invasive diagnostic and ther-
apeutic procedures (CWU+PET) or invasive diagnostic and therapeutic procedures alone (CWU). 
These procedures are governed by local routine, which is based on current guidelines.1-4 Randomisa-
tion was done centrally by computer, by a permuted block design, stratified by institute.
All procedures other than PET, including treatment and follow-up, were done in the referring hos-
pitals according to local standards. Follow-up consisted of regular visits (at least every 2–3 months) 
in the outpatient clinic. Trained data managers obtained all information up to 12 months after ran-
domisation.
We did PET scans with a Siemens ECAT EXACT HR+scanner (Siemens/CTI, Knoxville, TN, 
USA) at the Vrije Universiteit, Amsterdam. We asked patients to fast for 6 h before the scan. A 1-h 
whole-body acquisition started 60 min after injection of 370 MBq 18FDG. We imaged the mid-
femur-skull trajectory with emission scans for 5 min except for the chest, which was imaged with 
two 10-min scans followed by 5 min of transmission scanning. Images were reconstructed by filtered 
back-projection (Hanning 0·5; resolution after reconstruction 7 mm full-width at half-maximum) 
without attenuation correction. Results were communicated to the referring clinician by phone and 
confirmed in writing, with a hard copy of the PET scan included.
Two readers from a group of three assessed all PET scans; if necessary, consensus was reached with 
the third reader. Pulmonary and mediastinal lesions were visually associated with mediastinal back-
ground activity.23 Chest computed tomography (CT) scans and transmission-emission overlays de-
fined anatomical correlates for PET abnormalities and localised mediastinal foci.24
The PET report included information on nature of the primary lesion, mediastinal lymph-node 
involvement, and distant metastases, and concluded with an assessment of tumour-node metastasis 
(TNM) stage according to CT and PET and a suggestion for further workup. Referring clinicians 
used this information accordingly. However, potential distant or nodal metastases, which might 
have a major effect on patients’ management, were confirmed by other means. Unconfirmed PET 
findings were ignored.
The primary outcome measure was number of futile thoracotomies. We classified thoracotomy as 
futile for the following reasons: benign lung lesion; pathologically proven mediastinal lymph-node 







single lymph node established at mediastinal dissection;26 stage IIIB disease; explorative thoracoto-
my for any other reason; or recurrent disease or death from any cause within 1 year after randomisa-
tion.
Statistical analysis
Before the trial was designed, we assessed current clinical practice in a retrospective analysis of stag-
ing procedures in the two largest participating centres.8 On the basis of these results and of pub-
lished work about PET, we estimated that addition of PET to conventional workup might reduce 
the number of futile thoracotomies from 45% to 20%. Our sample-size calculation (power of 90%, 
of 0·05, two-sided) suggested that a total of 160 patients was required.27 Number of futile thora-
cotomies with respect to total number of patients randomised in each group was tested by χ2 test 
(intention-to-treat analysis). The same test compared nodal yield between both groups. In addition, 
we did tests that were based on exact inferences and that were stratified by institute. None of these 
approaches, however, led to important changes in results. Hence, for reasons of arithmetic simplic-
ity, we report unstratified χ2 tests and their CIs. Because of the low risk of PET imaging and the 
short accrual time, no interim statistical analysis was planned.
96 conventional work-up 
(CWU)
92 conventional work-up 
including PET (CWU+PET)
188 patients with suspected  
non-small cell lung cancer  
patients randomised
96 analysed for futile 
thoracotomy







Between January, 1998, and January, 1999, we enrolled 188 patients from nine hospitals (between 
five and 50 patients per hospital) – 96 in the CWU group and 92 in the CWU+PET group (figure). 
70% of patients in each group had clinical stage I/II disease (table 1). Pre-randomisation workup 
was closely similar for both groups, and included at least a chest CT scan, which usually included 
CWu (n = 96) CWu+Pet (n = 92)
Characteristic
Age (years, mean [SD]) 65 (10) 66 (10)
Sex
Men 75 (78%) 69 (75%)
Women 21 (22%) 23 (25%)
Karnofsky index
70-80 6 (6%) 10 (11%)
90-100 90 (94%) 82 (89%)
Weight loss >5% 15 (16%) 14 (15%)
Clinical stage
I 63 (66%) 58 (63%)
II 5 (5%) 6 (7%)
IIIA 22 (23%) 23 (25%)
IIIB 6 (6%) 4 (4%)
IV* 1 (1%)
Comorbidity
Vascular, diabetes mellitus 31 (32%) 30 (33%)
Chronic obstructive pulmonary disease 30 (31%) 23 (25%)
Previous malignancies 13 (14%) 17 (19%)
Definite diagnosis of non-small-cell lung cancer 46 (48%) 48 (52%)
Pre-randomisation imaging tests (CT of the thorax excluded) 56 (58%) 54 (59%)
Bone scan 26 (27%) 25 (27%)
CT/US of the abdomen 46 (48%) 42 (46%)
CT/MRI of the brain 3 (3%) 5 (5%)
CT/MRI of other area 1 (1%) 5 (5%)
Radiograph of other area 7 (7%) 10 (11%)
Data are number of patients (%) unless otherwise stated. CT = computed tomography; US = ultrasound; MRI = 
magnetic resonance imaging.
* Solitary brain metastasis on CT. 







the liver and adrenals (89%). All CT scans were done with at least third-generation scanners: spiral 
modality in 24%, with intravenous contrast in 55%, both equally distributed between each group. 
In both groups, 58% of patients underwent at least one additional test to identify metastatic disease 
(table 1). Two patients allocated to the CWU+PET group declined PET (figure). The other 90 
patients underwent PET a median of 3 days after randomisation (range 1-13).
Primary outcome
A significantly greater proportion of patients underwent futile thoracotomy in the CWU group 
than in the CWU+PET group (relative reduction 51%, 95% CI 32–80, p = 0·003; table 2). The ab-
solute difference of 20% can be interpreted as five patients (95% CI 3–14) who needed PET to avoid 
one futile thoracotomy. Apparently justified surgery was done in a closely similar proportion of 
patients in each group (table 2). Futile surgery happened irrespective of clinical stage: 46% (31/68) 
of patients with clinical stage I/II disease in the CWU group compared with 25% (16/64) of those 
in the CWU+PET group, and 29% (8/28) of those in the CWU group with clinical stage III disease 
compared with 11% (3/27) in the CWU+PET group, had futile surgery. Assessment of resectability 
by CT and PET was discordant in a third of cases, and PET was correct in two-thirds. In 37% of 
patients undergoing PET, CT was incorrect with respect to the primary outcome measure. This 
percentage was closely similar to the proportion of futile thoracotomies in the CWU group.
Our protocol required confirmation of clinically decisive PET results, thus the predictive value of 
PET alone (ie, without any confirmation) was analysed in 86 assessable patients. Six patients could 
not be assessed because they either declined PET (n = 2), had intercurrent morbidity prohibiting 
surgery (2), refused surgery (1), or had chemotherapy rather than surgery after revision of tumour 
histology (1). Six patients who died after apparently curative surgery were allocated to justified tho-
racotomy (table 3). PET correctly suggested that surgery was justified in 81% (95% CI 68–92) of 
scans, versus 71% (58–84%) in which PET suggested surgery was futile. Overall accuracy before veri-
fication was 76% (67–85%). Better preoperative assessment of patients in the CWU+PET group 
than in the CWU group was evident in three phases: before surgery with curative intent, at surgery, 
and during follow-up.
Before surgery with curative intent
After randomisation, 18 patients in the CWU group did not proceed to thoracotomy for the follow-
ing reasons (table 2): tumour-positive mediastinal lymph-node biopsy sample (n = 10); shrinking le-
sion at preoperative chest radiograph (2); adrenal metastasis diagnosed by revision of CT confirmed 
by fine-needle aspiration (1); small-cell lung cancer (2); cardiac disease prohibiting surgery (1); death 
due to local progression before surgery (1); and surgery declined (1). Thus, 78 patients underwent 
thoracotomy with curative intent.
63 patients (66%) underwent 67 mediastinal lymph-node staging attempts: mediastinoscopy, 62; 
mediastinotomy, four; video-assisted thoracoscopy, one. Of the ten patients with biopsy-proven 
mediastinal lymph-node involvement precluding surgery, in five, the final N-stage was diagnosed at 
CT-indicated mediastinal lymph-node stations; in two, CT suggested absent and hilar adenopathy; 
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and in three, confirmation was obtained at stations not enlarged at CT, one of which proved to 
have a contralateral-positive biopsy, rather than only ipsilateral involvement, as suggested by CT. 
25 patients underwent thoracotomy without additional staging procedures after randomisation: 22 
had cT1/2N0M0, two had cT2N2 (nodes not accessible by mediastinoscopy, and mediastinoscopy 
impossible after previous neck surgery, respectively), and one had cT3N0.
In the CWU+PET group, 32 patients did not proceed to thoracotomy for the following reasons 
(table 2): tumour-positive lymph nodes (n = 18; two after PET-guided lower cervical node biopsies); 
confirmed stage IV disease after PET (7; skeletal, liver, and adrenal metastasis confirmed by biopsy; 
cerebral metastasis by CT and magnetic resonance imaging); PET and clinical course suggesting be-
nign disease (3; two had a normal PET scan); intercurrent morbidity prohibiting surgical treatment 
(2); biopsy-confirmed neuroendocrine tumour treated with chemotherapy (1); and surgery declined 
(1). Thus, 60 patients in the CWU+PET group underwent thoracotomy with curative intent.
67 patients (73%) had 68 mediastinal lymph-node staging attempts: mediastinoscopy, 59; medias-
tinotomy, five; and rigid bronchoscopy, four. Of the 18 patients with biopsy-proven mediastinal 
lymph-node involvement precluding surgery, pathological N-classification was established at a CT-
enlarged nodal station in eight versus a PET-positive mediastinal lymph node in 16. In six patients, 
the final N-stage was diagnosed at sites shown by CT and PET (2N3, 4N2). In ten patients, only PET 
suggested the positive biopsy site (4N3, 6N2), five of which had a normal CT scan. In two patients, 
PET had suggested hilar adenopathy (N1) with positive biopsies of ipsilateral lower tracheobron-
cheal nodes (with CT read as N0 and N1, respectively). In three patients, the mediastinal lymph- 
node procedure had been done while awaiting confirmation of coexistent PET-suspected distant 
sites. Number of nodal stations sampled at mediastinoscopy was closely similar in each group.
In 13 patients without evidence of mediastinal lymph-node involvement on chest CT, PET sug-
gested otherwise, which was confirmed in six. Four patients could not be assessed for various reasons 
(patient refusal, exploratory surgery), and at thoracotomy, no mediastinal lymph-node involvement 
was noted in the remaining three patients. False-positive PET-suspected rib metastases were record-
ed in two patients (fibrodysplasia, trauma). 18 patients underwent thoracotomy without additional 
staging procedures after randomisation and PET: 17 had clinical stage cT1/2N0/1 and one cT1N2 
(nodes inaccessible by mediastinoscopy).
At surgery
Patients in the CWU and CWU+PET groups underwent thoracotomy at a median of 22 days 
(range 8–118) and 28 days (4–106), respectively. Number of patients proceeding to thoracotomy 
was significantly higher in the CWU group than in the CWU+PET group (table 2; p = 0·013). In 
the CWU group, 20 thoracotomies were futile versus nine in the CWU+PET group. 12 patients 
who had CWU were upstaged and seven had benign disease (table 2). In the CWU+PET group, six 
patients were upstaged and two had benign disease (table 2). In three of the patients with IIIA–N2 
disease, PET suggested mediastinal lymph-node involvement, which was not confirmed by medi-
astinoscopy. In both groups, one open-and-close procedure was done, since residual lung capacity 







In total, a closely similar number of different nodal stations were sampled in CWU and CWU+PET 
groups (mean 4·3 [SD 1·9] vs 4·6 [1·8], respectively). The yield of preoperative mediastinal lymph-
node staging was 63% in the CWU group compared with 83% in the CWU+PET group (p = 
0·16).
CWu (n = 96) CWu+Pet (n = 92)
No thoracotomy 18 (19%) 32 (35%)
Confirmed N2/3 10 18
Confirmed distant metastases 1 7
Benign primary lesions 2 3
Other tumour 2 1
Intercurrent morbidity, refusal 3 3
Thoracotomy 78 (81%) 60 (65%)
Non-futile thoracotomy 39 (41%) 41 (44%)
Futile thoracotomy 39 (41%) 19 (21%)
Benign 7 2
Explorative thoracotomy 1 1
IIIA–N2 6 4
IIIB 6 2
Table 2. Specification of primary outcome
During follow-up
In the CWU group, 14 patients developed clinically noticeable recurrences within 12 months of 
randomisation after apparently curative surgery. Patients relapsed with metastases in the brain (n = 
3), lymph nodes (2), bone (2), kidney (2), soft tissue (3), adrenal gland (1), and liver (1), with mul-
tiple sites in four patients. Most relapses arose beyond 180 days of randomisation. Nine of the 14 
patients who relapsed died during follow-up. Another four died of surgery-related causes, without 
clinical evidence of relapse. One patient died of reasons not definitely due to cancer or surgery. Of 
all patients who underwent surgery in the CWU group, 17 had distant metastases within the year of 
follow-up. In all but two patients, these sites had been screened before randomisation, or there had 
been no indication for such screening according to 1997 guidelines (n = 5).4
In the CWU+PET group, four patients relapsed after apparently curative surgery, two with bone 
metastases, and one with metastases in the brain and skeleton after refusal of a PET scan and un-
dergoing curative surgery (pT1N0M0). In the other patient, a pulmonary metastasis of melanoma 
(primary site unknown) had been resected, but disseminated involvement (skin, breast, adrenal) be-
came apparent during follow-up. All patients with recurrent disease were alive 12 months after ran-
domisation. Five patients died of surgery-related causes and one patient died of an unknown cause.
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Discussion
Our study showed that addition of PET to conventional workup can strikingly reduce the number 
of futile thoracotomies in patients with suspected potentially resectable non-small-cell lung cancer. 
The main effect of PET was to upstage patients (12% in the CWU group compared with 27% in the 
combined group). Obviating surgery in such patients improves patients’ management.
Our findings are directly applicable to clinical practice. Data from the Netherlands Cancer Regis-
try28 suggest that our study probably included about 65% of all eligible patients diagnosed in these 
nine hospitals.
Our definition of futile thoracotomy as operationalisation of health outcome of PET in potentially 
resectable non-small-cell lung cancer is based on consensus of current surgical management of non-
small-cell lung cancer in the Netherlands, and is supported by international guidelines.1,3 Non-cura-
tive surgery unnecessarily increases burden of disease and risk. The life expectancy of patients with 
locally advanced non-small-cell lung cancer might improve if they receive preoperative or neoad-
juvant treatments, including chemotherapy or chemoradiation.29 If resection in any cancer patient 
who survived clinically disease-free for 1 year had been deemed to be justified (rather than futile, 
classified in this trial by perioperative IIIA-N2/IIIB stage), the overall conclusion would be much 
the same (39% vs 16% futile surgery in the CWU and CWU+PET groups, respectively; p = 0·001). 
Likewise, if surgery for benign disease and non-cancer-related death were excluded, there would still 
be a difference (29% vs 13% respectively; p = 0·007). Only one patient (in the CWU+PET group) 
was reported with minimal N2 disease at thoracotomy.
Unexpected distant metastases during follow-up were noted in tissues that had been screened or 
in patients who were not at risk in accordance with the guidelines.4 Our finding of 8% confirmed 
distant metastases in the CWU+PET group is slightly below figures from other studies,12,13,30,31 in 
which 11–14% unexpected distant metastases have been reported.
Thoracotomy no thoracotomy total
Justified futile Justified futile
Thoracotomy indicated by PET
Yes 33 6* 2† 0 41
No 13‡ 6§ 26¶ 0 45
* Benign disease in two patients, advanced disease in four.
† PET suggested hilar lymph-node involvement, but mediastinoscopy was positive.
‡ PET suggested benign disease in one, advanced disease in 12 (including patients in whom PET could not exclude 
mediastinal lymph-node involvement adjacent to the primary tumour.
§ Thoracotomy and follow-up showed advanced disease.
¶ PET suggested benign disease in three, advanced disease in 23. 







In retrospect, mediastinal lymph-node staging procedures were fully compliant with 1997 interna-
tional guidelines4 and were done in about two-thirds of patients. In the CWU group, the sensitivity 
of these efforts was about 60%, which is closely similar to results from other multicentre trials.10 
Although our trial was not designed to address the issue, our data suggest a high yield of invasive 
preoperative mediastinal lymph-node staging if guided by PET of suspected nodes. At the time 
when our trial was designed (in 1997),32 the interaction between PET and mediastinoscopy was 
unclear. Rigorous accuracy studies13,33 have since shown that the negative predictive value of PET 
for mediastinal lymph-node involvement could be sufficiently high to refrain from mediastinoscopy 
in non-central tumours.
Some aspects typically associated with management of patients, as opposed to diagnostic accuracy, 
became apparent during our trial. First, because 18FDG uptake does not always suggest malignancy, 
and surgery is the only chance of cure for most patients with non-small-cell lung cancer, PET find-
ings that would preclude surgical treatment need to be verified. This requirement is supported by the 
estimated diagnostic accuracy of PET alone in this study (table 3). The claimed superior accuracy – 
eg, mediastinal lymph-node involvement versus CT11,13 – needs to be translated into relevant out-
come measures, ie, into cases upstaged by preoperative biopsy rather than at surgery with curative 
intent. Even if false-positive PET findings might not adversely affect the ultimate result of workup, 
they are likely to invoke additional tests, generating an unnecessary burden on the patient, delay, and 
costs.
Second, clinical decision-making takes into account the complete diagnostic profile of the patient, 
and not merely the result of a single test. Therefore, a patient with a clinical and radiological pro-
file strongly suggesting malignancy underwent thoracotomy despite a PET-negative primary lesion. 
This decision was justified in retrospect (diagnosis of bronchioloalveolar cell cancer). Finally, in 
some cases, preoperative radiological follow-up already suggested benign disease and obviated sur-
gery. PET would not have affected this decision. Such data cannot be derived from accuracy studies 
because of masking for the new procedure, and are difficult to model in decision analysis.34
In conclusion, addition of PET to standard workup in routine clinical practice improved selection 
of surgically curable patients with non-small-cell lung cancer.
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Cost-effectiveness of FDG-PET  
in staging non-small cell lung cancer:  
the PLUS study




Currently, up to 50% of the operations in early-stage non-small cell lung cancer (NSCLC) are 
futile owing to the presence of locally advanced tumour or distant metastases. More accurate 
pre-operative staging is required in order to reduce the number of futile operations. The cost-
effectiveness of fluorine-18 fluorodeoxyglucose positron emission tomography (18FDG-PET) 
added to the conventional diagnostic work-up was studied in the PLUS study. Prior to invasive 
staging and/or thoracotomy, 188 patients with (suspected) NSCLC were randomly assigned 
to conventional work-up (CWU) and whole-body PET or to CWU alone. CWU was based 
on prevailing guidelines. Pre-operative staging was followed by 1 year of follow-up. Outcomes 
are expressed in the percentage of correctly staged patients and the associated costs. The cost 
price of PET varied between € 736 and € 1,588 depending on the (hospital) setting and the pro-
curement of 18FDG commercially or from on-site production. In the CWU group, 41% of the 
patients underwent a futile thoracotomy, whereas in the PET group 21% of the thoracotomies 
were considered futile (P = 0.003). The average costs per patient in the CWU group were € 9,573 
and in the PET group, € 8,284. The major cost driver was the number of hospital days related 
to recovery from surgery. Sensitivity analysis on the cost and accuracy of PET showed that the 
results were robust, i.e. in favor of the PET group. The addition of PET to CWU prevented 
futile surgery in one out of five patients with suspected NSCLC. Despite the additional PET 
costs, the total costs were lower in the PET group, mainly due to a reduction in the number of 
futile operations. The additional use of PET in the staging of patients with NSCLC is feasible, 







Lung cancer is the leading cause of cancer-related death in Western society. In 1997 in the Nether-
lands, approximately 8,800 people were diagnosed with lung cancer and 8,650 patients died from 
the disease.1 The 5-year survival rate was 13%.1 The poor prognosis of lung cancer can be ascribed 
to the high rate of unresectable disease at diagnosis and the failure of other treatment modalities to 
cure metastatic disease. Non-small cell lung cancer (NSCLC), for which surgery is the only curative 
treatment option, represents approximately 85% of all primary lung tumours. 
Diagnostic work-up is essential to confirm the diagnosis of NSCLC pre-operatively and to detect 
(mediastinal) lymph node involvement and distant metastasis. The aim is to restrict surgery to pa-
tients who will potentially benefit. 
International guidelines have been formulated to optimize these efforts, but daily clinical practice 
remains variable.2 The current diagnostic work-up cannot prevent futile surgery in up to 50% of pa-
tients with NSCLC.3 Recently, the situation has improved significantly owing to the introduction 
of positron emission tomography with fluorine-18 fluorodeoxyglucose (18FDG-PET).4 Results of a 
randomized clinical trial showed that PET, employed in addition to conventional diagnostic work-
up, could reduce futile operations by 50%.5 
The clinical relevance of PET in NSCLC is beyond doubt; however, health policy makers are con-
cerned about the extra costs accruing from the introduction of this new technology. PET is a rela-
tively expensive technique due to the high costs of acquisition, maintenance and the radioactive 
tracer.6,7 A number of economic evaluation studies have examined PET in various diagnostic path-
ways through modeling. Most of these variants showed that PET could be cost-effective in NSCLC 
when added to conventional work-up (CWU). However, all of these studies had to rely on many 
assumptions and were unable to consider how cumulative diagnostic patient information impacts 
on patient management and final outcomes. 
In the PET in Lung Cancer Staging (PLUS) study, the effectiveness of PET added to the CWU 
compared with CWU alone was studied in a randomized fashion consistent with routine clinical 
practice.5 A cost-effectiveness analysis was anticipated in this trial. The results of this analysis are 
presented here. The perspective of the study was the hospital’s point of view, i.e. all hospital costs 




Between January 1998 and January 1999, patients with suspected or proven NSCLC, considered to 
be medically operable and to have potentially resectable disease by the referring physician on the 
basis of clinical staging, but not surgical staging, were invited to participate. Patients were randomly 
assigned either to PET followed by CWU (CWU+PET) or to CWU alone. CWU was based on 
existing guidelines and involved further invasive diagnostic and therapeutic procedures. Eight gen-
eral hospitals and one university hospital recruited patients for the study. 
PET scans were performed using a Siemens ECAT EXACT HR+ scanner (Siemens/CTI, Knox-
ville, Tenn., USA) at the Vrije Universiteit, Amsterdam. Referring clinicians were free to use the in-
formation and to act accordingly. However, potential distant or nodal metastases, which might have 
a major impact on patient management, had to be confirmed by other techniques. Unconfirmed 
PET findings were to be ignored. All procedures other than PET, including therapy and follow-up, 
were performed in the referring hospitals according to prevailing local standards. Follow-up con-
sisted of regular visits (every 2-3 months) to the outpatient clinic for 12 months. The clinical paper 
contains a detailed description of the procedure.5 
Procedure Cost (range)
X-ray 35  (33-35)
Abdominal ultrasound 57  (24-74)







Hospital day (general ward) 220 (187-216)
ICU hospital day 1,080 (898-1,238)
VATS, Video-assisted thoracic surgery
aBronchoscopy was performed with an inflexible bronchoscope, and was therefore performed in an operation room 
bCost due to inpatient stay was not included in the cost of the procedure, but was part of the cost of hospital days 







We focused on the costs of diagnostic and therapeutic strategies. The cost items considered were 
hospital days, thoracotomies, and invasive and non-invasive diagnostic tests (including PET). Ther-
apeutic interventions such as chemotherapy and radiotherapy were not taken into account. 
The full costs of the various diagnostic procedures, hospital days and intensive care days and opera-
tion costs were calculated by using the bottom-up method.8,9 These costs included costs for person-
nel, materials, depreciation and overheads based on 1999 prices. The cost price study was performed 
in all hospitals. Where individual hospitals were not able to deliver details on specific procedures, 
average costs of similar procedures at the other hospitals were used. Table 1 contains the average cost 
prices for relevant procedures with ranges. 
The costs of PET encompass the personnel costs, the depreciation and maintenance costs, the mate-
rial (tracer) costs and overheads. A PET study requires a minimum level of radioactive activity, and 
because 18FDG has a half-life of 110 min, the quantity supplied depends on the period between 
production and usage in the patient. The PET centre was provided twice a day with enough 18FDG 
for the scheduled patients. The production and supply of 18FDG is therefore constrained by two fac-
tors, a maximum that can be injected in the patient and a minimum level of radioactivity necessary 
for PET to work. 
The costs of PET also depend on the daily number of scans, the average time per scan, and the amount 
and expertise (e.g. salary) of the personnel involved. 
Several scenarios were considered by varying the number of PET scans performed per day and vary-
ing the hospital setting. The “expensive” variant involved a PET study performed in a university 
hospital with on-site tracer production and with clinical (diagnostic) as well as research functions. 
In this calculation, it was assumed that eight PET scans were performed daily, requiring the presence 
of a nuclear medicine technologist and a nuclear medicine physician. This variant was based on real 
costs in one centre. 
The next two variants were based on expert opinion, because in the Netherlands there were only two 
university hospitals with a PET centre at the time of our study. In the “cheap” variant, 12 PET scans 
per day were performed in a community hospital with a PET scanner which was incorporated in a 
nuclear medicine department, and merely used for clinical diagnostic work. Production and trans-
port of 18FDG were done according to the satellite concept.7 The “in-between” option considered a 
large community hospital in which eight PET scans were performed per day. In this setting, limited 
research was done and 18FDG was produced on site. 
Table 2 shows a detailed specification of the cost of a PET scan. In this study we used the “in-be-
tween” variant. In this variant the costs of a whole-body FDG-PET scan amounted to € 1,020. The 
upper and lower values were used in a sensitivity analysis. 
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Outcomes 
Primary study outcome was the number of futile thoracotomies. A thoracotomy was classified 
as futile in cases of: (1) a benign lung lesion, (2) pathologically proven mediastinal lymph node 
(MLN) involvement (stage IIIA-N2) other than minimal N2 disease (i.e. intranodal involvement 
in a single lymph node established at mediastinal dissection), (3) stage IIIB disease, (4) explorative 
thoracotomy for any other reason, or (5) recurrent disease or death from any cause within 1 year after 
randomization. 
Patients were analyzed according to the intention-to-treat principle. Secondary outcome was the 
cost associated with both strategies calculated as the average cost per (suspected) NSCLC patient. 
Sensitivity analysis 
Sensitivity analyses were performed on the efficacy of PET and the PET setting. For the efficacy the 
95% confidence interval was used and for the setting the “expensive” variant and the “cheap” variant 
were taken. 
Statistical analyses 
The number of futile thoracotomies was tested by the chi-square test based on intention to treat. 




Table 3 presents the baseline characteristics. Seventy-one percent of the CWU patients and 70% of 
the CWU+PET patients had clinical stage I or II. Pre-randomization work-up was similar for both 
groups and included at least a chest computed tomography (CT) scan, which included the liver and 
adrenals (89%). In both groups, 58% of patients underwent at least one additional test to identify 
metastatic disease before randomization. 
Cheap variant “in between” variant expensive varianta
Personnel 160 208 570
FDG/material 227 245 259
Depreciation/maintenance 227 302 481
Overhead 123 264 277
Total 736 1,020 1,588
aIncluding research 






Table 3. Baseline characteristics, clinical study 
The primary outcome is the proportion of patients who underwent futile thoracotomy: in the CWU 
arm, 41% (39/96) underwent futile surgery compared with only 21% (19/92) in the CWU+PET 
arm (P=0.003) (Table 4). This implies a relative reduction in the number of futile surgical proce-
dures by 51%. The absolute difference of 20% corresponds to five patients (95% confidence inter-
val 3–14) needing CWU+PET to avoid one futile thoracotomy. Eighteen patients in the CWU 
arm and 32 in the CWU+PET arm did not proceed to thoracotomy, mainly due to the presence 
of benign lesions, upstaging due to detection by PET or intercurrent morbidity and recurrence of 
metastases. Eighteen percent of the CWU patients and 32% of the CWU+PET patients were not 
operable owing to extensive co-morbidity or refusal of the patient. Unfortunately, in both arms 
several patients died due to surgery-related complications. Apparently justified surgery was done in 
a closely similar number of patients in each group, namely 39/96 in the CWU group and 41/92 in 
the CWU+PET group. 
CWu (n=96) CWu+Pet (n=92) 
Mean age (years, SD) 65 (10) 66 (10)
Male sex, n 75 (78%) 69 (75%)
Karnofsky index
 70-80 6 (6%) 10 (11%)
 90-100 90 (94%) 82 (89%)
Weight loss >5% 15 (16%) 14 (15%)
Clinical stage
 I 63 (66%) 58 (63%)
 II 5 (5%) 6 (7%)
 IIIA 22 (23%) 23 (25%)
 IIIB 6 (6%) 4 (4%)
 IV 0 1 (1%)
CWu (n=96) CWu+Pet (n=92) 
Thoracotomy 78 (81%) 60 (65%)
 Non-futile surgery 39 (41%) 41 (44%)
 Futile surgery 39 (41%) 19 (21%)
No thoracotomy 18 (19%) 32 (35%)
Table 4. Primary outcome of the clinical study 
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Cost analysis
Considering the groups of operative patients and all patients, the mean number of regular hospital 
days and number of days on the intensive care ward were in favor of the CWU+PET group. The 
number of imaging tests and (non-)invasive tests did not differ between the groups (except for the 
PET scan). Also the number of mediastinoscopies was similar in the two arms (63 patients in the 
CWU group and 67 patients in the CWU+PET group). The most important cost items are shown 
in Table 5. 
The group of patients who were not operated on consisted of patients who refused an operation or 
patients who had severe co-morbidity (six patients), were down- or upstaged (41 patients) or were 
discovered to have a tumor type for which surgery was not the optimal treatment (three patients). 
Overall, the average total costs were lower in the PET group owing to a reduction in (futile) opera-
tions and subsequent hospital days (Table 6). Patients who underwent surgery in the CWU arm 
cost € 11,486 on average, versus € 10,709 in the CWU+PET arm. Patients who underwent futile 
operations in the CWU group cost on average € 12,473, compared with € 13,689 in the CWU+PET 
group. This difference is mainly related to the cost of PET (€1,021) in the CWU+PET arm. Remark-
ably, non-futilely operated patients cost on average € 10,489 in the CWU group and € 9,487 in the 
CWU+PET group. This difference was mainly caused by a higher number of intensive care days due 
to one patient in the CWU group, who stayed 61 days on the intensive care ward. 
CWu CWu+Pet
Operated patients
 No. (%) 78 (81%) 60 (65%)
 Mean no. of (non-)invasive tests 1.6 1.8
 Mean no. of general hospital days (SD) 19.8 (18.6) 14.9 (10.1)
 Mean no. of IC days (SD) 4.7 (9.3) 4.0 (7.1)
Non-operated patients
 No. (%) 18 (19%) 32 (35%)
 Mean no. of (non-)invasive tests 1.8 1.9
 Mean no. of general hospital days (SD) 4.5 (6.7) 8.6 (13.6)
 Mean no. of IC days (SD) 0.1 (0.24) 0.3 (1.4)
All patients
 No. 96 92
 Mean no. of (non-)invasive tests 1.6 1.9
 Mean no. of general hospital days (SD) 16.9 (18.0) 12.7 (11.7)
 Mean no. of IC days (SD) 3.8 (8.5) 2.7 (6.1)






The average costs of patients who were not operated on amounted to € 1,287 in the CWU group and 
to € 3,851 in the CWU+PET group. The costs in the CWU group were lower because the patients 
spent fewer days in the hospital and because of the cost of PET itself. 
Sensitivity analysis
The results of the sensitivity analysis are presented in Table 7. 
CWu CWu+Pet
Operated patients
 Imaging tests – 13 (51)
 (Non-)invasive tests 279 (193) 288 (191)
 PET – 970a (224) 
 Surgeryb 1,576 (359) 1,637 (425)
 General hospital ward 4,543 (4,177) 3,439 (2,260)
 IC ward 5,088 (10,099) 4,362 (7,744)
 Total costs (median; SD) 11,486 (8,020; 12,628) 10,709 (8,621; 7,727)
Non-operated patients
 Imaging tests 2 (8) 38 (69)
 (Non-)invasive tests 226 (208) 318 (171)
 PET – 1,021 (0)
 Surgeryb – –
 General hospital ward 999 (1,466) 1,987 (3,222)
 IC ward 60 (255) 373 (1,524)
 Total costs (median; SD) 1,287 (416; 1,609) 3,736 (2,521; 4,137)
All patients
 Imaging tests 0 22 (59)
 (Non-)invasive tests 269 (196) 298 (184)
 PET 0 988 (182)
 Surgeryb 1,281 (698) 1,068 (855)
 General hospital ward 3,879 (4,057) 2,934 (2,707)
 IC ward 4,145 (9,304) 2,975 (6,582)
 Total costs (median; SD) 9,573 (7,480; 12,072) 8,284 (7,592; 7,462)
SD, Standard deviation
a Two patients refused PET imaging 
b Including re-intervention surgery due to complications 
Table 6. Average costs (SD) of CWU and CWU+PET (costs in Euros) 
2
Varying the efficacy of PET 
In this study adding PET to CWU resulted in a 20% absolute reduction (from 41% to 21%) in futile 
operations or, put another way, one prevented unnecessary surgical procedure for every five PET 
scans (95% CI: 3–14). The 95% confidence interval corresponded to a range of one prevented un-
necessary surgical procedure for every three PET scans (9% futile operations remaining in the PET 
group) to one prevented procedure for every 14 PET scans (28% futile operations remaining). Tak-
ing into account the cost of €1,021 per PET scan, the more efficient PET result would result in higher 
savings compared with CWU. Preventing 28% of the futile operations would result in a difference of 
€2,123 in favor of CWU+PET. Even the upper boundary of the 95% CI would result in a difference 
of €759 in favor of CWU+PET. 
Varying the setting of PET 
The results of the cost analysis were rather sensitive to the price of PET. If the PET costs were lower 
than €1,021, the savings in favor of the PET+CWU arm would increase. Furthermore, the PET costs 
in the “expensive” setting were still in favor of the PET+CWU group. The break-even point, i.e. 
with no difference in costs between the groups, was at a PET cost of €2,350. If the costs of PET were 
higher than €2,350, then the CWU group would be cheaper. 
Varying the setting and the efficacy of PET 
Varying both the setting and the efficacy of PET, most results were robust and in favor of the 
PET+CWU group. When taking into account the highest price of PET and the worst efficacy out-
come, the results were in favor of the CWU arm (namely €542). 
setting/cost of Pet
no. of futile operations remaining after Pet
8 19 26 36
Cheap variant: Euro 736 –2,401 –1,565 –1,033 –274
“In between” variant: Euro 1,020 –2,123 –1,289 –759 0a
Expensive variant: Euro 1,588 –1,571 –741 –212 +542
a Break-even point 
Table 7. Sensitivity analysis on the efficacy and the setting of PET: difference compared with cost of CWU (cost 







The introduction of PET as a new diagnostic technology for various indications is clinically an im-
portant step, but the costs may be relatively high. In this randomized controlled trial we directly 
measured the efficacy of PET as well as the associated costs. Our study shows that PET added to 
CWU in patients with suspected NSCLC is effective from either perspective. Since hospital days, 
the operation itself and postoperative intensive care were the major cost drivers, a decrease in futile 
operations would have a profound effect on the costs. 
Until now, cost-effectiveness data on PET could only be derived from studies that applied modeling 
techniques to estimate the costs and benefits of PET in various diseases,10-17 and mainly in (sus-
pected) lung cancer. The results of these studies have been based on reviews of the sensitivity and 
specificity of CT and PET. Morbidity and mortality effects have scarcely been reported, and have 
been reliant upon additional assumptions made by the investigators. Diagnostic accuracy measures 
do not easily translate to the complete clinical decision-making and management of patients and 
subsequent clinical outcome. Further, one of the main deficiencies of these analyses is a failure to 
consider how cumulative diagnostic information impacts on patient management and final out-
comes.15 However, improved accuracy in pre-operative staging should provide an improvement in 
survival.18 
A limitation of our study is the neglect of pre-operative or neoadjuvant treatments for patients with 
locally advanced NSCLC or other treatment options for patients who were unsuitable for thora-
cotomy. However, it has been claimed that multimodality interventions are cost-effective.6 
The real costs of a PET scan are complicated to assess. In the Netherlands, the application is relatively 
new and no guidelines regarding indications for PET have been established at the national level. 
Furthermore, the acquisition cost of a PET scanner varies between €1,000,000 and €2,800,000, so 
that the depreciation per scan can vary considerably. The daily production of PET scans is an impor-
tant determinant of the calculated price of a PET scan. Since clinical PET may comprise research as 
well as diagnostic activities, the daily production of diagnostic scans may range from 6 to 12. There-
fore the cost of PET shows considerable variation within the hospital setting. 
The possible configurations for PET and cyclotron have also been described elsewhere. In the United 
States, Keppler et al. found a range between $2,986 and $1,557 (i.e. between €2,706 and €1,411) (in-
cluding radioactive FDG) for a whole-body PET scan.13,14 In our study, the break-even cost of PET 
(in which the average costs per NSCLC patient would have been equal in both arms) was €2,234, . 
This cost price of PET was much higher than the cost in the most expensive scenario (i.e. a university 
hospital with a research function). In this scenario the cost price amounted to €1,588. 
In some countries, PET scans are reimbursed by insurance companies. In the USA, reimbursement 
amounts to approximately $2,000 (18FDG included) for PET staging in lung cancer. In Germany 
the reimbursement amounts to €1,227.11 In the Netherlands, the results of this study could be used 
for the reimbursement policy. Here, about 9,000 new lung cancers are detected annually. About 85% 
of these are NSCLC. After exclusion of those patients who prove to have irresectable disease after 
standard dissemination tests and those who are inoperable owing to co-morbidity precluding sur-
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gery, approximately 5,000 patients would be eligible for PET. Applying the results of this trial, the 
routine use of PET for NSCLC could save a great number of thoracotomies, resulting in a decrease 
in morbidity and resource use (i.e. intensive care), with a consequent saving of around 6.4 million 
euros (5,000 × €1,289). 
Recently a second randomized controlled trial of PET in NSCLC was closed after including a total 
of 470 patients. The primary research question of this study is whether PET may substitute for other 
techniques in the conventional work-up. Again, data on costs will be collected in detail and analyzed 
as a secondary endpoint. 
On the basis of this study we conclude that the additional use of PET in the staging of patients with 
NSCLC is feasible and safe and saves costs from a clinical and an economic perspective. 
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The VU Medical Centre serves a population of 2.5 million people and so, in 1996, when it was de-
cided that the Centre would acquire a dedicated positron emission tomography (PET) scanner, it 
was anticipated that diagnosticians and clinicians would soon be confronted with a lack of scan ca-
pacity. Decisions would need to be made on which clinical indications and, within those indications, 
at what point in the diagnostic work-up PET would be most beneficial. Our main concern was to 
try to ensure equity of access to this new technology. We insisted that routine use of PET should be 
restricted to those applications where it would have a clinically meaningful impact, reasoning that 
waiting lists are not compatible with routine patient care. In cancer care, most of the literature on 
the use of PET focused on non-small cell lung cancer (NSCLC), which was also the most common 
cancer in terms of incidence. Moreover, a retrospective study in our region identified a relevant clini-
cal problem in lung cancer diagnosis.1
Although accuracy studies showed that PET improved diagnostic performance, it was unclear how 
and to what extent these results might affect management and patient outcome. Direct evidence did 
not exist on whether the addition of PET to conventional staging in daily clinical practice would 
lead to a clinically relevant reduction of unnecessary operations for patients with suspected resect-
able NSCLC. We decided that randomized trials would provide the most reliable and convincing 
answer to this uncertainty. Randomization provides broad comparability of groups except for the 
diagnostic device being assessed and thereby ensures a non-biased assessment of the value of the 
experimental technique with respect to clinically relevant outcomes. Although randomization in 
diagnostic research is slowly becoming more accepted, it appears that the value of randomized trials 
is still disputed.2-5 All aspects that used to be seen as challenges to the use of randomization for as-
sessing medical interventions in the 1970s, such as the difficulties of performing randomized trials, 
their adequacy and their conclusiveness, are now being raised as arguments against randomized tri-
als of diagnostic techniques.6
This paper describes practical situations in which randomization would be feasible and efficient. 
These arguments will be followed by a discussion on methodological issues that need special con-
sideration.
Accuracy and beyond
In NSCLC, evaluation of the extent of spread in the mediastinum is an important step in deciding 
about further therapy. In general, patients with pre-operative identifiable N2 disease are excluded 
from thoracotomy. Conventional work-up of the mediastinum often includes non-invasive imaging 
with computed tomography (CT) followed by invasive exploration through mediastinoscopy. In a 
recently published meta-analysis of 18 studies, including more than a thousand patients, the negative 
predictive value of PET was found to be 93%, which is at least as good as that of mediastinoscopy 
in daily clinical practice.7 However, improved diagnostic performance does not necessarily translate 
into meaningful changes in clinical decisions, even at the level of this relatively simple diagnostic 
problem. In fact, in spite of the burgeoning number of PET studies, the 2003 guidelines on NSCLC 
staging8 do not clearly recommend that mediastinoscopy can be omitted if a PET scan is negative.






 studies, because the design of such studies requires that the new imaging technique is assessed out 
of the clinical context. For example, clinically relevant PET findings (such as the suspicion of a dis-
tant metastasis in an otherwise resectable cancer) need to be confirmed because of the risk that this 
might be a false positive finding.9 Since this is not allowed in the context of an accuracy study on 
mediastinal staging it needs to be proven that such confirmation is feasible in daily clinical practice.10 
Further, in clinical practice compared with accuracy studies, it is less common to have dichotomous 
test results,11,12 and grey areas prevail with grading of diagnostic suspicion arising from a variety of 
test results. This contributes to the difficulty of assessing how the technique will perform in clinical 
practice when it is used in combination with other diagnostic interventions. How will the clinician 
use the newly provided diagnostic information and how will this affect the performance of other 
investigations and treatment?
In many ways, the level of information provided by accuracy studies can be compared to that from 
phase II studies in the evaluation of treatments. These studies are a prerequisite in the process of 
building evidence of activity, but not suited to producing information on the difference between the 
effects of a new drug and those of other competing drugs or devices in routine practice.13
Alternatively, decision analyses can be used to estimate the effect of various strategies on cost and 
effectiveness outcomes. Because the input measures are usually obtained from accuracy studies that 
often do not comply with quality standards14-16 and assumptions are required to make the problem 
tractable,5 this technique is also unsuitable when faced with the complexity of daily clinical practice 
and the need to make decisions with respect to clinically meaningful outcomes. Nevertheless, in the 
presence of many alternative diagnostic strategies, such an approach may be helpful in identifying 
the most promising diagnostic tests or algorithms for further research.17
The extent to which a patient may ultimately benefit from the addition of a new imaging technique 
(in terms of reduction in iatrogenic toxicity or improvement in survival) can only be investigated 
through a comparison of the full implementation of PET added to conventional staging versus the 
conventional process alone. The benefit of the diagnostic interventions will often be no more than 
moderate, just like the experiences with therapeutic interventions. In such circumstances, then, just 
as with treatments, it is important that the comparison is done in such a way that both systematic 
and chance effects are minimized as much as possible. Balancing both known and unknown prog-
nostic variables by randomly assigning some patients to the new test and others to the control group 
is the most efficient way to do this, along with making the study as large as possible. The process of 
random assignment will mean that the diagnostic test should be the only difference between the 
two groups. As well as minimizing imbalances in prognostic factors, randomized studies also have 
several qualities and benefits that arise not from the act of random allocation itself, but from the fact 
that they have many features of high-quality research.18 A written protocol provides transparency, 
the pre-calculation of a sample size often allows some exploration of patient and tumor characteris-
tics that might be outcome related, and direct cost comparisons are also possible.
We conclude that randomized studies are important in advancing diagnostic technology beyond the 
level of accuracy. However, several issues bear consideration.
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Outcome measures
Conventionally, the outcome of most randomized studies is measured in terms of patient mortal-
ity and morbidity. However, diagnostic tests serve to allocate appropriate management to patients. 
Thus, as long as the new test does not alter the definitions of staging and management for each stage 
is already established, a reasonable outcome measure for such studies will be the extent to which 
appropriate therapy is applied. With NSCLC, there was a broad agreement among clinicians that 
treatment options would be clear when the diagnostic process had been completed. In addition, 
because PET did not produce a new stage classification, a suitable outcome measure could be the 
reduction of iatrogenic morbidity (translated into unnecessary operations) rather than survival.19
However, in some situations, new tests may identify new prognostic subsets. Then, the result of the 
test might affect both the diagnosis and the intervention. A randomized trial with mortality-related 
outcomes would then be needed to assess the effect of the test. We will illustrate this with two 
examples. The sentinel node biopsy (SN) in breast cancer was developed merely to reduce the num-
ber of unnecessary axillary dissections. Later, it became clear that the procedure also induced stage 
migration: the single biopsied (sentinel) node allowed a much more thorough histopathological 
evaluation than had been feasible with the 15-20 nodes typically harvested from an axillary specimen 
of a woman with breast cancer. This meant that prognostic and, therefore, treatment issues might be 
affected: implementation of the SN biopsy might unintentionally lead to overtreatment of women 
if they received adjuvant therapy from which they could derive no benefit. This is close to the notion 
of a “false positive sentinel node”.
In the evaluation of non-Hodgkin’s lymphoma, fluorine-18 fluorodeoxyglucose (FDG) PET dis-
criminates responders and non-responders much better than the current CT strategy.20 It might be 
expected, therefore, that this would lead to improved survival because of the earlier recognition of 
therapy failure (by PET compared with clinical follow-up) and the initiation of second-line therapy. 
However, to assess this reliably requires a direct, randomized comparison of FDG-PET versus rou-
tine management.
In summary, the choice of the outcome should be considered carefully with respect to the potential 
effect of the diagnostic process on stage and management, but it is not necessarily restricted to sur-
vival.
Applicability
As with randomized trials of treatments, the most valid estimate of the (cost) effectiveness of a diag-
nostic test is likely to come from multiple multicenter trials. However, especially in large pragmatic 
trials, the variability in the control groups may be larger than that found in trials of therapy, and the 
added value of the new technique relates to the yield from the standard procedures, without the new 
test. In a setting in which the outcomes for patients undergoing diagnostic procedures without the 
new test are very different from those for the control patients in the trial, the effect found in the trial 
might not be applicable. Therefore, the first step in trying to apply the trial’s results to a local situa-
tion is to analyze the extent and yield of current diagnostic practice in that setting. This is best done 






“The times, they are a-changin’”
There is concern that technology proceeds so rapidly that a device tested in complex randomized tri-
als may be outdated by the time that these are analysed and reported.2 We believe that this argument 
is often over-stated. Since the introduction of whole-body FDG-PET in oncology, the technique 
has not essentially changed for at least a decade. If there had been a switch to outcome-oriented stud-
ies as soon as accuracy studies suggested clinically relevant benefit, time could have been saved.
It is only if a new technology is so obviously better and costs less, that randomized assessments of it 
will not be necessary. Examples of such technologies are extremely rare.
Recently, integrated PET-CT scanners have been introduced. There is no doubt that image quality 
and ease of interpretation will strongly appeal to clinicians. An important improvement in diag-
nostic accuracy in NSCLC staging has already been reported.11 If this development leads to better 
staging and a corresponding impact on patient management, a single-step diagnostic work-up may 
be within reach. The downside is that shortages of scan capacity will be even greater than we faced 
in 1997 with the introduction of the old PET scanner. However, whether the improved accuracy 
claimed for the integrated device will solve the residual clinical problems of PET visually correlated 
with CT scans and indeed lead to better patient outcomes remains to be demonstrated. We doubt 
whether improved T-staging by PET-CT fusion will make surgeons refrain from potentially cura-
tive resection. Further, to what extent will the proportion of equivocal results encountered in daily 
practice be reduced and will this indeed lead to improved management? Currently, with limited 
availability of the new technology, an ideal window of opportunity exists for randomized trials and 
international collaborative action should be sought to perform such studies.
In conclusion, there are good arguments in favour of randomization in diagnostic research. The 
results of randomized trials provide the reliable evidence base needed for clinical decision-making. 
The PLUS study,19 investigating FDG-PET in NSCLC staging, shows that pragmatic randomized 
trials are feasible. Unless there are compelling reasons to the contrary, randomized studies should 
be required for new diagnostic interventions. These studies should use clinically relevant outcome 
measures and be conducted as early as possible in the evaluation of the new technology.
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evaluating  
positron emission tomography  
in non-small-cell lung cancer:  
moving beyond accuracy to outcome
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summary
Accuracy measures of diagnostic tests usually do not allow an appropriate assessment of its 
(cost-)effectiveness in clinical practice. Since test results are seldom ‘black or white’ and are 
usually part of a complex work-up process, the benefit in overall patient outcome is prefer-
ably measured by comparing the diagnostic process including the new test concurrently with 
the prevailing diagnostic work-up. Obviously, a trial should be preceded by formal analyses of 
residual (in)efficiency of the prevailing diagnostic work-up and of the potential diagnostic and 
therapeutic impact of the new test. This hierarchical approach as described by Fryback and 
others is generally considered the optimal way to evaluate new and costly diagnostic imaging 
devices.39 However, practical examples of this stepwise process related to a particular device or 
indication, especially with regard to outcome levels beyond accuracy, are scarce. This chapter 
presents a series of coherent studies that have been performed to evaluate the use of PET for 
specific disease indications in cancer with clinically relevant endpoints beyond accuracy. These 
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Note: the sharp elements in figure 1b indicate that these processes may continue in time. The dotted element with 
rounded edges indicates a step that has not been studied in full depth. 
Figure 1. Theoretical hierarchical approach to development, assessment and implementation of new diagnostic tech-
nology (A) and framework of study designs, beyond accuracy to outcome, applying the theoretical approach (B).
A B
introduction
The introduction of new technology in health care is often accompanied by a fundamental dilemma: 
rapid diffusion inspired by the perspective of considerable clinical benefit versus adequate evalua-
tion followed by implementation in appropriate clinical situations. This dilemma was recognized 
shortly after the introduction of computed tomography (CT) in 1973 in the United States,1 and 
again with the introduction of magnetic resonance imaging (MRI) a decennium later.2 Compared 
to therapeutic interventions, the evaluation of a diagnostic test is particularly challenging because 
the results may be less directly translatable into health outcome. The value of plain radiography 
to diagnose bone fracture is unquestionable, and its result directly dictates patient management. 
However, when clinical decision-making is multifactorial and test results are imperfect, improved 
diagnostic accuracy provided by one component of a diagnostic test sequence may not necessarily 
translate into meaningful therapeutic changes. Obviously, without evidence of changes in therapeu-
tic decisions, the implementation of new tests is unlikely to have any impact on health or costs. 
A hierarchical approach to the assessment of diagnostic imaging technology has been advocated 
by experts in health technology assessment (Figure 1A).3 The framework typically assumes that 
evaluation of technical and image quality and diagnostic performance (sensitivity and specificity) 
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is followed by assessment of diagnostic and therapeutic impact. Then, effectiveness on patient and 
societal outcomes needs to be measured, and the process is completed by defining costs and benefits 
of the implementation. Although this approach has been cited and discussed frequently in the litera-
ture neither CT nor MRI was assessed accordingly before clinical adoption. 
Typically, the first two levels were studied extensively but the implementation of the technique was 
independent of evidence from the levels beyond accuracy. Another 20 years later, positron emission 
tomography (PET) was embraced with similar excitement, but has limitations.4 Although studies 
on the accuracy of PET have been improved by using methodological and reporting guidelines,5 
research to establish the role of PET in changing patient outcome and cost-effectiveness failed to 
appear. Current constraints on health care resources and the limited availability of the technique in 
our situation stimulated us to develop a program to evaluate the clinical role of 18F-Fluorodeoxyglu-
cose-PET.
The case of 18F-Fluorodeoxyglucose – positron emission tomography
In 1996 the VU Medical Center (VUmc) acquired a dedicated PET scanner; at that time 
the second scanner in the Netherlands. The VUmc serves a population of 2.5 million peo-
ple; thus a lack of scan capacity was to be anticipated. Data were urgently needed to decide 
for which clinical indications and, within those indications, at what point in the diagnos-
tic work-up 18FDG-PET would be most beneficial. This system is mostly suggested as an 
‘add-on’ technique, but it might also substitute for other diagnostic procedures. Our main 
concern was to ensure equity of access to this new technology. To avoid waiting lists, we re-
stricted 18FDG-PET to clinical research and to those applications where sufficient evidence 
for a clinically meaningful impact was available.
In this chapter, first, the strengths and limitations of accuracy studies will be summarized, exempli-
fied by the situation in non-small-cell lung cancer (NSCLC). Then, a series of coherent studies will 
be presented with endpoints beyond the level of diagnostic accuracy. This framework follows the 
hierarchical approach for the assessment of new technologies (Figure 1B). The framework is not 
intended to be a tight straitjacket that will fit all diagnostic devices. It should merely be considered 
an illustration of our experience with various steps that contributed to the successful accomplishing 
of two randomized controlled trials that we performed with PET in NSCLC. The results of these 
trials were implemented in guidelines, which subsequently changed the situation of patients with 
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Diagnostic accuracy of positron emission tomography in non-small-cell lung cancer
In NSCLC, evaluation of the extent of disease in the mediastinum is an important step in deciding 
about further therapy. In general, patients with preoperative identifiable N2 disease are excluded 
from thoracotomy. Conventional work-up of the mediastinum often includes non-invasive imaging 
with CT, followed by invasive exploration through mediastinoscopy. In a meta-analysis of 18 studies, 
including more than a thousand patients, the negative predictive value of PET was found to be 93%, 
which is at least as good as that of mediastinoscopy in daily clinical practice.6 However, improved 
diagnostic performance does not necessarily translate into meaningful changes in clinical decisions, 
even at the level of this relatively simple diagnostic problem. In fact, in spite of the burgeoning 
number of PET studies, the 2003 guidelines on NSCLC staging7 do not clearly recommend that 
mediastinoscopy can be omitted if a PET scan is negative.
Moreover, in general it will be impossible to measure impact on clinical outcomes in accuracy stud-
ies, because the design of such studies requires that the new imaging technique is assessed out of the 
clinical context. For example, clinically relevant PET findings (such as the suspicion of a distant 
metastasis in an otherwise resectable cancer) need to be confirmed because of the risk that this 
might be a false positive finding.8 Since this is not acceptable in the context of an accuracy study on 
mediastinal staging, it needs to be proven that such confirmation is feasible in daily clinical practice.9 
Further, in clinical practice compared with accuracy studies, it is less common to have dichotomous 
test results,10 and grey areas prevail with grading of diagnostic suspicion arising from a variety of 
test results. This contributes to the difficulty of assessing how the technique will perform in clinical 
practice when it is used in combination with other diagnostic interventions. How will the clinician 
use the newly provided diagnostic information and how will this affect the performance of other 
investigations and treatment?
In many ways, the level of information provided by accuracy studies can be compared to that from 
phase II studies in the evaluation of treatments. These studies are a prerequisite in the process of 
building evidence of activity, but not suited to producing information on the difference between the 
effects of a new drug and those of other competing drugs or devices in routine practice.
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The framework
Our PET-evaluation strategy started some years before the actual installation of the PET-scanner in 
our region. Details of these steps in this framework are discussed below (Figure 1B).
i. Literature Analysis
When searching for evidence for determining the value of a diagnostic imaging technique, typi-
cally data on diagnostic accuracy dominate the literature. Aggregation of such data should be done 
in a systematic review. Standards for the design, execution and reporting of accuracy studies and 
subsequent meta-analysis are now in place: in doing so we recommend applying the guidelines of 
the Cochrane Collaboration on reviewing techniques (www.cochrane.org) and initiatives such as 
Standards for Reporting of Diagnostic Accuracy (STARD)5  and the Quality Assessment of Studies 
of Diagnostic Accuracy included in Systematic Reviews (QUADAS) instrument11  for reporting 
diagnostic accuracy and for assessing the quality of accuracy studies, respectively. Without posi-
tive results from accuracy studies, preferably summarized in systematic reviews, higher-level efficacy 
studies are not warranted. 
In 1996, a comprehensive report from the MDRC Technology Assessment Program was 
published with a systematic review of the literature on 18FDG-PET as a diagnostic test for 
potential applications mainly in neurology, cardiology, and oncology.12 Motivated by posi-
tive accuracy studies further research was suggested to define the impact of 18FDG-PET on 
treatment decision making and on outcomes, in comparison with existing techniques. 
ii. Exploiting Clinical Data Obtained Prior to the Introduction of a New Test
A. Signaling (in-) efficiency and assessing potential yield in daily practice.
To assess the potential benefit of a new test in clinical practice, it is necessary to have detailed knowl-
edge of the situation prior to the introduction of that test. Local facilities, individual expertise, and 
diagnostic work-up practices may vary substantially even within a relatively small geographic area.13 
Due to such variations, potential benefit of a new device may differ between hospitals or practices. 
Furthermore, the observed level and nature of the (in-) efficiency provides the parameters required 
for sample sizes and other statistical considerations of new studies, Finally, data on the regional 
situation will help to interpret results from other studies and to assess the generalizability. Prefer-
ably such studies are performed on patient files and electronic registries because those reveal the 
actual behavior. Inclusion of different types of institutes will improve external validity of the results 
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We reviewed clinical practice, yield, and costs of preoperative staging for suspected NSCLC 
in the medical records of all patients diagnosed between 1993 and 1995 in an academic and 
a large community hospital.13 Crosslinking with the Dutch Cancer Registry and the Patho-
logical Anatomical National Registry provided complete surgical, histopathological, and 
follow-up data. We found a high adherence to international guidelines, despite practice 
variation between the two hospitals. Hospitals differed in the setting of diagnostic staging 
(hospitalization, outpatient setting) and the extent of mediastinoscopy use. Approximately, 
half of the operations for presumed resectable NSCLC proved futile. We linked this to limi-
tations of the diagnostic tests undertaken at each level of the TNM staging process. Together 
with the literature survey on 18FDG-PET, these data clearly indicated that there was room 
for improvement in the pre-operative diagnostic process by 18FDG-PET. 
B. Mining Histopathological Data. 
In oncology, stored surgical specimens can also provide useful information on the potential impact 
of a new diagnostic test. The example hereunder illustrates this.
When several studies claimed that 18FDG-PET had a high accuracy and hence could qualify 
for  lymph node staging in breast cancer and melanoma,14,15 we were very skeptical as these 
results were counter-intuitive with our experience of histopathological staging of sentinel 
node biopsies. We measured tumor volumes obtained in sentinel node biopsies and found 
that the tumor load in malignant lymph nodes was far below that which might be detected 
by 18FDG-PET.16,17 Subsequently, large prospective clinical studies confirmed these find-
ings.18-20 In our in-vitro melanoma study16 we combined physical PET principles and epide-
miological data to conclude that only a select group of patients might have sufficient tumor 
volumes to be detected by 18FDG-PET. Consequently, reviewing existing datasets rather 
than performing (expensive) prospective clinical studies led us to conclude that PET should 
not be used routinely for lymph node staging in breast cancer and melanoma.
Obviously, these first steps of the framework (literature analyses and assessment of clinical data prior 
to the introduction of the technique) can be done simultaneously.
iii. Decision Modeling
Decision analysis models the cost-effectiveness of a new diagnostic device. The model can combine 
results of clinical studies that cover different health care steps. In the presence of many alternative 
diagnostic strategies, decision analysis can help to identify the most promising diagnostic tests or 
algorithms for further research.6,21 The data input is usually based on a meta-analysis of accuracy 
studies.21 Unfortunately, accuracy studies often fail basic quality standards (e.g., independence of 
test interpretation, sample size, and case selection).22,23 In addition, decision analyses studies require 
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a large number of assumptions to make decision problems tractable.3 As a consequence, decision 
analysis is often only of limited value when faced with the complexity of daily clinical practice and 
the need to make decisions with respect to clinically meaningful outcomes. As more information is 
generated via clinical studies, fewer assumptions are required for decision modeling.24 
With the input of the data collected in two Dutch hospitals we considered three PET sce-
narios in a modeling approach: PET upfront in every patient suspected of NSCLC (1), PET 
after standard imaging, but prior to invasive staging (2) and PET only in patients considered 
operable and resectable after medical imaging and mediastinoscopy (3). From a cost perspec-
tive, the second option was considered most promising.24
iv. ‘Clinical-Value’ Studies
Studies that determine therapeutic plans before and after the application of a new test are sometimes 
referred to as ‘clinical-value’ studies25 or simply ‘before-after’ studies.26 By means of questionnaires, 
assessments of diagnostic probabilities and provisional treatment plans are made, first without the 
information contributed by the imaging device and then with the information.27 In a third question-
naire the physician is asked to retrospectively grade the usefulness of this additional information in 
diagnostic understanding and the choice of therapy.
Credibility of such studies depends on a high quality design. Specific clinical questions should be 
addressed, consecutive (unselected) patients presenting with a clinical problem should be entered 
and changes in diagnostic certainty and therapeutic choices should be described in sufficient detail.26 
Even with attention to these issues, limitations of the clinical value study include discrepancies be-
tween the reported intention and actual clinical behavior, expectation bias, and limited generaliza-
tion. The clinical value design is most useful when the availability of the new technique is still lim-
ited; in the run-up to more complex randomized studies every patient subjected to the technique 
can be included to provide relevant information. Standardized feed-back also helps learning from 
experience of both clinicians and diagnosticians. Further, in rare diseases and indications where 
randomized controlled trials (RCTs) are impossible, the clinical-value study may be the highest level 
of evidence possible.  
Since its introduction at the VUmc in 1997 the effect of every 18FDG-PET scan was evalu-
ated prospectively. Clinicians completed questionnaires just before, immediately after, and 
several months after the scan to study diagnostic understanding and management changes. 
In three years more than 600 consecutive patients were included (response 95%); half of 
those were referrals from outside the VUmc. Diagnostic understanding increased signifi-
cantly in more than 70%, and management was changed for the benefit of the patients in 
40% of all cases. The added value of the scan differed by indication. A subgroup was referred 
to the 18FDG-PET center because of suspected NSCLC28 with diagnostic dilemmas, such as 
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standing in 84% and beneficial management changes in 50%, mostly cancelled surgery (35%). 
Appreciation of 18FDG-PET increased with time. Studies with similar designs in Australia29 
and the Unites States30 also reported significant management changes (67 and 61%, respec-
tively) due to 18FDG-PET. 
If a clinical-value study fails to show improved diagnostic understanding or therapeutic impact of 
an indication it should probably be removed from the list of potential cost-effective tests, whereas 
promising results warrant further investigation.
v. Randomized Controlled Trials
The extent to which a patient may ultimately benefit from the addition of a new imaging technique 
(e.g., in terms of a reduction in iatrogenic toxicity or improvement in [disease-free] survival) can 
only be investigated through a comparison of the full implementation of the technique added to, 
or in (partial) substitute of the conventional process. As only moderate benefit on patient outcome 
should be expected from any innovation, it is essential that both systematic and random errors are 
minimized. Balancing both known and unknown prognostic variables by randomly assigning pa-
tients to the new test or to the control group is the most efficient way to minimize error. Random-
ized controlled trials also have several qualities and benefits that arise not from the act of random-
ization itself but from the fact that they have many features of high-quality research31: a written 
protocol provides transparency, the pre-calculation of a sample size often allows some exploration 
of patient and tumor characteristics that might be outcome related, and direct cost comparisons are 
possible in a ‘real-life’ setting.
Several aspects are of particular importance for RCTs involving diagnostic imaging. In therapeu-
tic RCTs the outcome is usually measured in terms of patient mortality and morbidity. However, 
diagnostic tests serve to allocate appropriate therapy to patients. A reasonable outcome measure 
for such studies is the extent to which appropriate therapy is applied, depending on the condition 
that the new test does not alter the definitions of staging, and treatment for each stage is already 
established. For example, there was a broad agreement among clinicians that treatment options of 
NSCLC patients would be clear when the diagnostic process had been completed. In addition, be-
cause 18FDG-PET did not produce a new stage classification, a suitable (intermediate) outcome 
measure could be the reduction of iatrogenic morbidity (translated into unnecessary operations) 
rather than survival.32 
For many diagnostic tests it is likely that they will first be applied as ‘add-on’ to conventional work-up. 
This is a relatively straightforward and safe approach. The moment of addition can be clearly defined 
in terms of logistics, as it is only necessary to have access to the technique within a reasonable time 
frame. However, for some tests the challenge is to study whether it can be applied earlier in the diag-
nostic process and may substitute other procedures. In such cases relevant endpoints could be short-
ening the work-up period, reducing morbidity by obviating invasive procedures, or reducing costs. 
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The strategy in the control group determines the extent of the contrast, and is therefore essential for 
the interpretation of the results. Usually the choice is between current clinical practice and ‘state-
of-the-art’ procedures. Current clinical practice, carefully documented as the control strategy, will 
provide meaningful answers for the clinical community involved.3 Our baseline study showed vari-
ances in clinical work-up between hospitals. However, through several interdisciplinary sessions in 
the preparation phase of the RCT, a common diagnostic workup protocol could be agreed upon.
In 1998 nine hospitals in our region enrolled 188 patients suspected for potentially resect-
able NSCLC. These patients were randomly allocated to the conventional work-up approach 
or to the same approach with 18FDG-PET performed just prior to mediastinoscopy or tho-
racotomy.32 The trial included about 65% of all eligible patients who were diagnosed in these 
institutes during that year. 18FDG-PET-positive findings had to be confirmed by histology 
or ignored. In the conventional work-up group patients were managed as in our retrospective 
study. In the 18FDG-PET add-on group the number of futile thoracotomies was reduced by 
50%. The fact that hat objective criteria for endpoints, and clinical consensus about manage-
ment of patients after diagnosis are important, is illustrated by a recently published second 
RCT of 18FDG-PET in NSCLC.33 In our study, ‘futile thoracotomy’ pertained to objective 
criteria (e.g., benign lung lesion, histopathological criteria, stage IIIB disease, explorative 
thoracotomy for any other reason or recurrent disease, or death from any cause within 1 year 
after randomization), whereas in the Australian trial the surgeon’s decision was taken as the 
gold standard without validation against follow-up information (e.g., early recurrence).34
Our next RCT of 18FDG-PET in NSCLC addressed the question of replacing conventional 
work-up with a 18FDG-PET-scan, as had been simulated in the modeling study.24 Between 
1999 and 2001, 465 patients were enrolled by 23 hospitals. The study showed that application 
of 18FDG-PET as the initial test had similar overall accuracy compared to traditional work-
up but failed to reduce the number of tests.35 
The result of RCTs on a diagnostic test (-sequence) should be seen in the context of patient manage-
ment. In our area, there was clinical consensus that combined modality therapy (including neoad-
juvant chemotherapy) should be given in case of locally advanced NSCLC. However, if an obser-
vational study on a diagnostic test identifies new prognostic subsets with unclear implication for 
therapy, a RCT should follow to evaluate the result of various interventions by subset rather than a 
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vi. Economic Evaluation 
One of the advantages of adding an economic evaluation to a RCT is the possibility of concurrent 
data collection, having the diagnostic test as the essential contrast. Health technology assessment of-
fers a range of techniques for the evaluation of health care activities. The most common approach to 
economic evaluation in diagnostics is a cost-effectiveness analysis. In this type of analysis, outcome 
is expressed in natural units such as operations avoided or life years saved. Direct and indirect costs 
can be distinguished. Direct costs are defined as the resources related to the study intervention, e.g., 
inpatient admission, medical procedures, surgery, pharmaceutical drugs, and laboratory tests. In 
economic evaluations these costs are always taken into account. The importance of the other types 
of costs depends on the research question and the perspective (e.g., societal or payer).36
 
Several factors are specific to costing of diagnostic procedures. Diagnostic equipment is usually ap-
plied to many indications. For example 18FDG-PET is also applied to other oncological and non-on-
cological indications. From an economic point of view the number of 18FDG-PET scans performed 
for these indications should also be taken into account in the calculation of the cost-price of one 
scan. However, when the procedure is cost-effective for a certain indication one cannot automati-
cally assume the total production capacity being filled up with this indication. In theory, one would 
want to tailor the required capacity of diagnostic equipment to the cost-effectiveness for different 
indications. Another dilemma emerges when the capacity to perform the procedure is limited. This 
may either result in waiting lists, or, for the sake of the RCT, priority can be given resulting in unre-
alistically short waiting times. In such cases indirect non-medical costs of waiting times should also 
be considered in the economical evaluation. 
Our RCT on add-on 18FDG-PET provided direct data for comparison of costs in relation to 
diagnosis and therapy. Scenario analyses included various hospital settings, tracer accessibil-
ity and scenarios for 18FDG-PET-scan usage.37 All scenarios proved favorable for PET. The 
major cost driver was the number of hospital days related to recovery from surgery.
vii. Before-and-After Implementation  
Studying the situation before-and-after the implementation of the procedure including 18FDG-PET 
closes the circle of studies evaluating the cost-effectiveness of a new diagnostic device. A full ap-
preciation of the technique should take into account all perceptions, quality, and costs of its imple-
mentation.
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Data from the Regional Cancer Center Registry, where the PLUS-study was active, indicated 
that the results have a substantial and lasting impact. Since the guidelines were implemented 
in 2000, the number of lung resections dropped with an absolute 20% (corresponding to an 
estimated 50% reduction in unnecessary thoracotomies) compared to the average over the 
five years preceding to that (Figure 2).38 A formal study is planned to investigate perceptions, 
























Figure 2. Number of lung resections before and after the implementation of a guideline on the use of Positron 
Emission Tomography in non-small cell lung cancer in 2000. The region of the Comprehensive Cancer Centre 
Amsterdam where the guideline was introduced serves 2.6 million inhabitants (Source: Netherlands Cancer 
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Positron Emission Tomography (PET) is a relatively new nuclear medicine imaging technique that 
allows the visualization of biochemical processes in tissues. Therefore, PET has the ability to com-
plement traditional imaging modes such as computed tomography (CT) and magnetic resonance 
imaging (MRI), which provide information on anatomical structures. When, in 1996, a dedicated 
positron emission tomography (PET)-scanner was planned in the VU University Medical Centre, it 
was decided to focus the clinical PET research to the identification of cost-effective applications in 
routine cancer practice. This thesis provides the theoretical back-bone of this process and describes 
its application in non-small cell lung cancer.
In chapter 1 an introduction is given to the complexities of diagnosing and staging of disease in 
general and of non-small-cell lung cancer (NSCLC) in particular. The actual situation of manage-
ment of NSCLC had just been studied in two hospitals in the geographical region of interest and 
showed substantial residual shortcomings.1 It was found that in nearly 50% of operated patients 
surgical intervention failed because of irresectable tumor, benign lesions at surgery or because the 
disease recurred or metastasized within one year. At the same time, PET with 18F-fluorodexoyglu-
cose (FDG-PET) had shown promising results in accuracy studies in several aspects of the NSCLC 
staging.2 However, improved accuracy does not necessarily imply clinical usefulness, e.g. better pa-
tient management and improved clinical outcome.3 The assessment of the value of a diagnostic test 
to patient management best follows a multi-phase hierarchical process, as has been described by 
Fryback and others.4 The process encompasses the technical aspects of the test such as image quality 
and reproducibility, diagnostic accuracy, diagnostic and therapeutic impact, patient outcomes and 
finally, the cost-benefit analysis of the introduction of the technology. Obviously, demonstration of 
efficacy at each lower level is logically necessary, but not sufficient, to assure efficacy at a higher level. 
Given the promising data from accuracy studies and prompted by the result of modeling studies 5 we 
considered that evaluation of the added value of FDG-PET should preferably be investigated in a 
direct comparison of the conventional strategy with a strategy that included the new device as ‘add-
on’. To minimize potential bias in that comparison, due to measurable and non-measurable patient- 
and tumor characteristics and diagnostician/clinician decisions, we started to plan a randomized 
controlled trial (RCT). 
To explore and improve our understanding of the potential impact of FDG-PET on management 
decisions in the preoperative setting of NSCLC, we first designed a ‘clinical value’ or ‘before-after’ 
study (chapter 2). Through prospective use of serial questionnaires, physicians were asked to indi-
cate their diagnostic understanding and planning for subsequent diagnostic or therapeutic steps, just 
before, immediately after and several months after learning the results of the PET-scan. Patients with 
suspected NSCLC were referred to the PET-center because non-invasive tests had failed to solve a 
diagnostic problem, usually unclear radiological findings. Based on 164 patients, the study revealed 
that PET had a positive influence on diagnostic understanding in 84% of cases and, according to the 





most frequently reported changes in treatment after PET (35%). Overall PET proved to be the key 
diagnostic tool in one of every four patients referred to PET. 
For the purpose of designing the diagnostic RCT we performed a literature search (in 1996, which 
was reiterated in 2005) to find other randomized diagnostic imaging studies. In chapter 3 the re-
sults of this investigation are presented. We designed a taxonomy of diagnostic RCTs (D-RCTs) 
accounting for main study contrasts and outcome measures. Applying this taxonomy, we were able 
to investigate possible time trends with respect to D-RCTs addressing patient outcomes as a func-
tion of imaging tests. Our first search included three distinctive years of publication between 1990 
and 2002 at intervals of 6 years to allow capturing possible developments in time. In a second search 
we focused on D-RCTs performed between 1990 and 2005, in which Magnetic Resonance Imaging 
(MRI) played a major role in the comparison. MRI is the most recent tomographic imaging device 
before PET, and we expected similarity of the respective assessment processes. In our non-specific 
search for D-RCTs, the majority of identified studies (82%) pertained to testing different tracers or 
acquisition parameters with one particular device. An increase over time was observed in studies 
comparing devices vs. studies testing tracers. In the end, we could identify only 15 D-RCTs in which 
patient outcomes were studied. The disease indications varied from cardiovascular and musculosk-
eletal problems to cancer. In the second search we identified 13 D-RCTs studying the value of MRI 
in the past 15 years. Four of those were published in 2005 and 4 others between 2000 and 2005, 
suggesting an increased interest in D-RCTs. Three of the 13 studies applied two contrasting tests or 
strategies in the same patients. In the other 10 studies, patients were randomly allocated to a strategy 
with or without MRI. Based on these results, we concluded that, although generally advocated and 
appreciated, randomized controlled trials in diagnostic imaging are not frequently performed. As a 
consequence, evidence on (cost)-effective use of imaging tests is lacking in general.
Because our literature search revealed that D-RCTs are relatively rare and certainly non-existent in 
the field of PET research, we considered it useful to publish and communicate about the design and 
its logistics (Chapter 4).7 The study was named the ‘PLUS study’ (PET in LUng cancer Staging). 
Patients were eligible if they had suspected or proven NSCLC, considered medically operable and 
potentially resectable by the local pulmonary physician on the basis of clinical staging procedures 
(i.e. clinical stage I-III). Patients were randomly allocated, just before invasive verification or therapy 
was considered, to either ‘continue as usual’ or to undergo a PET-scan. Of particular interest was 
the choice of outcome: we defined the primary endpoint as the difference in the number of futile 
thoracotomies between both groups. Thoracotomy was considered futile in case of benign lesions, 
pathologically proven mediastinal lymph node involvement (stage IIIA-N2), stage IIIB, explorative 
thoracotomy for any reason or recurrent disease or death of any cause within one year after random-
ization. The protocol required confirmation of clinically decisive PET results. Next to secondary 
endpoints, such as morbidity and duration of diagnostic and therapeutic processes, a separate costs 
analysis was planned. The study was powered to detect an absolute reduction of futile thoracotomies 
of 25% (power of 90%, alpha of 0.05 two-sided), assuming a 45% futile thoracotomy rate in the 
current setting as documented by our retrospective cohort analysis. Analyses would be performed 
according to the intention-to-diagnose principle. 
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In one year, 188 patients were included from nine hospitals.8 Data from the Dutch Cancer Registry 
suggested that the study included 65% of all eligible patients. 96 patients were randomized to the 
conventional group (CWU) and 92 to the CWU + PET group (Chapter 5). In each group, 70% of 
patients had clinical stage I/II disease. A significant greater proportion of patients underwent futile 
thoracotomy in the CWU group than in the CWU + PET group. The relative reduction was 51% 
(p = 0.003) and the absolute difference 20% (41% futile thoracotomies in the CWU group). This 
result can be interpreted as five patients who needed PET to avoid one futile thoracotomy. PET 
correctly suggested that surgery was justified in 81% of scans, versus 71% in which PET suggested 
surgery was futile. The main effect of PET was to upstage patients.
Together with clinical data, data on cost items were collected. Cost items included invasive and 
non-invasive tests (including PET), thoracotomies and hospital days on an individual and hospital 
level. The costs of PET encompassed the personnel costs, the depreciation and maintenance costs, 
the material (tracer) costs and overhead. The cost price of PET varied between € 736 and € 1,588 
depending on the hospital setting and the FDG availability.9 The average costs per patient in the 
PLUS-CWU group were €9,573 and in the CWU+PET group €8,284. The major cost driver proved 
to be the number of hospital days related to recovery from surgery. A sensitivity analysis, varying 
the efficacy of PET showed that the cost results are robust in favor of PET (Chapter 6). In addition 
to the straightforward cost analysis within the PLUS-setting, three scenarios were considered by 
varying number of PET scans performed per day and varying hospital settings. An ‘expensive’ sce-
nario considered PET in a university hospital, with on-site tracer production and with clinical and 
research functions. In a ‘cheap’ variant, 12 clinical PET-scans were made in a community hospital 
with FDG production and transport from elsewhere. The ‘in-between’ option represented a large 
community hospital with on-site FDG production, 8 PET-scans per day and limited research func-
tions. The scenario analyses, using the point-estimate of efficacy of PET but varying the setting also 
proved to be favorable for PET, even in the expensive setting. Only when the worst efficacy (1 futile 
thoracotomy prevented for every 14 PET-scans) was applied to the expensive variant (university set-
ting), the results were in favor of the CWU approach (namely €542).
Not every expert endorses the need for diagnostic randomized controlled trials.10 Moreover, unnec-
essary use of resources and ethical considerations are used to argue against D-RCTs. This prompted 
us to explicate our thoughts about the value of randomization in diagnostic research (Chapter 7).11 
Briefly put, the extent to which a patient may ultimately benefit from the addition of a new diag-
nostic imaging technique (in terms of reduction of iatrogenic toxicity or improvement in survival) 
can only be investigated in a concurrent comparison of conventional strategies in a routine clini-
cal setting without having to make unrealistic or unverifiable assumptions. Balancing both known 
and unknown prognostic variables by randomly assigning patients to the new and the conventional 
strategy is the most efficient way to do this, along with making the study as large as possible. As well 
as minimizing imbalances in prognostic factors, randomized studies also have several qualities and 





features of high-quality research, such as transparency on the base of a written protocol and a pre-
calculated sample size, to mention a few. 
The two randomized studies with FDG-PET in NSCLC that we performed show that pragmatic 
trials are feasible, although the window of opportunity may be limited. The PLUS study accrued 
188 patients with clinical stage I-III in one year. The POORT study, in which PET was tested at the 
very first suspicion of lung cancer to substitute other tests in number, enrolled 465 patients 2 years.12 
The fact that PET-capacity in the Netherlands was limited at that time may have contributed to that 
success.
In Chapter  we comprise our experience on the evaluation of cost-effectiveness of FDG-PET for 
different indications, and present a framework which basically follows the postulated hierarchical 
approach for the assessment of new technologies as referred to earlier. The starting point of our 
studies was a notion of residual inefficiency which might be amenable with the suggested improved 
accuracy of FDG-PET (in NSCLC). Retrospective cohort analysis substantiated this notion, speci-
fied the nature of the errors and it proved to be the main incentive for clinicians to participate in 
further research. The run-in experiment on the clinical value of PET was the learning curve of diag-
nosticians and clinicians. In the end, the coherence of this approach contributed to a very fruitful 
environment for collaboration and has facilitated the successful completion of the two RCTs and 
the appearance and implementation of working guidelines in our region. 
The present
Anno 2006, the PET-situation in the Netherlands has changed substantially. The PET-scanner ca-
pacity has increased dramatically and currently most hospitals have access to fixed or mobile PET-
scanners. In the Amsterdam region at least five scanners are available in a radius of about 20 ki-
lometers. From 2004 evidence based guidelines for diagnosis and management in NSCLC have 
incorporated PET on a national level.13 Ongoing studies are performed to update and refine these 
guidelines. It is estimated that in about 80% of the patients in the IKA region (2.6 million inhabit-
ants, 1300 NSCLC annually) with suspected operable NSCLC a PET-scan is integrated in their 
work-up. A recent analysis on data from the region of the comprehensive Cancer Center of Am-
sterdam suggested an absolute 20% decrease in the number of thoracotomies (corresponding to an 
estimated 50% reduction in unnecessary thoracotomies) compared to the average over the five years 
preceding to that.14
Since the advent of the PET-scanner, improvements in the concept of the scanner and other tech-
nologies have seen the light. After 15 years of whole body PET, the integrated or hybrid PET-CT 
scanner has been introduced.15-17 Several studies have claimed that the ‘hardware’ fused whole body 
anatomical (CT) and functional (PET) images have superior accuracy compared to software fusion 
or visual fusion (side-by-side reading, as employed in the PLUS study). A quick search in MED-
LINE revealed five studies investigating the accuracy of the integrated PET/CT as compared to 
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the other devices in NSCLC staging 18-22. All five studies suggested an improved accuracy for PET/
CT compared to side-by side reading of PET and CT or PET alone and two of them also claimed 
changes in patient management.22,21 However, the primary question should be what the size and 
the nature of any residual inefficiency in current NSCLC staging are (with PET integrated). Even 
though we are confident that adding the PET to standard diagnostic procedures reduces the number 
of thoracotomies, we know from the PLUS study that 20% of the thoracotomies is still unnecessary. 
To assess whether the integrated PET-CT could have prevented these thoracotomies we looked 
at the individual cases: In 9 patients of the PLUS study, the thoracotomy itself proved to be futile 
and in another 10 patients the disease recurred or the patients died early (within one year). Of the 
former 9 patients, 2 had benign disease, six were upstaged and one patient was not radically operated 
because the residual lung capacity precluded the pneumonectomy. In 3 of these 6 upstaged patients 
a mediastinoscopy had not been able to confirm the mediastinal lymph node involvement as sug-
gested by PET. In the 10 patients in which the surgery was considered futile in the follow-up-year, 4 
patients relapsed after apparent curative surgery, two with bone metastases and one with metastases 
in brain and skeleton after refusal of a PET. In the other patient pulmonary metastases of melanoma 
(primary site unknown) had been resected but disseminated involvement became apparent during 
follow-up. Five patients died of surgery related causes and one patient died of unknown cause. To 
conclude, more sophisticated non-invasive staging could have prevented at the most 3 of the 19 futile 
cases on the totality of 92 patients seen with PET. We recognize that these numbers are small and do 
not allow firm conclusions. However, they might give some indication of the expected yield of PET-
CT in the context of preventing unnecessary surgery. Compared to PET alone, PET-CT clearly 
adds to the specificity of PET readings, and as a clinical spin-off confirmatory biopsy procedures 
might be conducted more efficiently. In the PLUS study, lower cervical lymph nodes positive at 
PET proved to be a major challenge for radiologists in community hospitals. However, such failed 
confirmative procedure did not affect the number of futile thoracotomies since lymph node involve-
ment could be confirmed otherwise (albeit more invasively). With respect to the impact of PET-CT 
on sensitivity: we have argued that test results are not dichotomous, and this is why PET-CT, even 
though it consists of the same PET and CT scanning technologies as in the stand-alone situations, 
might help to flip the coin towards higher levels of suspicion. However, if the suggestion raised 
by our PLUS study evaluation of residual problems after PET is correct, we do not expect major 
incremental benefits on that level. Claims about improved staging at the level of the primary tumor 
extension20 obviously need confirmation given the limited resolution of PET.23 Perhaps alternative 
techniques to explore the mediastinum preoperatively are more promising. Endoscopic esophageal 
and endobronchial ultrasound-guided fine needle aspiration (EUS- and EBUS-FNA) are novel 
minimally invasive techniques with potential for the analysis of mediastinal lymph nodes partially 
complementary to mediastinoscopy and of tumor invasion in centrally located tumors.24
Alternatively, in case of PET-CT, logistic factors may prevail that justify a switch to this modality, 
even when increments of clinical effectiveness or lower costs are unlikely or difficult to prove. The 
concept of staging a patient with a single scan (‘one-stop-shop’) rather than with a battery of tests 





spective. Moreover the perspective of reducing the PET-scan time per patient should be appealing 
for those currently confronted with waiting lists. 
At the end of the day, whichever methodological concerns we might have about the evidence of su-
periority of PET-CT vs. PET, the industrial development is such that PET-CT will be the standard 
of practice soon, simply because whole body PET scanners are no longer being sold. An unsolved 
issue is whether PET-CT should be implemented upfront in the diagnostic process or just prior 
to mediastinal evaluation: it is not economical to perform PET-CT on every patient if CT alone 
would eliminate a considerable number of surgical candidates by showing disseminated disease or 
benign primary pulmonary lesion. Decision analysis preferably based on collected information of 
actual costs and scenario analyses can help to clarify this issue. 
So far, we have discussed FDG-PET in the context of surgical decision-making purely in terms of 
TNM staging issues. However, metabolic information obtained by FDG PET also adds prognostic 
information at the biological level within clinical stages.25 high uptake in tumors is prognostically 
unfavorable compared to lower uptake. Even though lack of standardized PET procedures impairs 
meta-analysis of individual studies again, the point seems to be made. How this information may 
be combined with other prognostic markers to develop strategies to improve the relatively poor 
outcome of patients with resectable lung cancer remains to be shown, but it is likely that systemic 
therapy will be required in subsets of patients. A similar prognostic feature of PET might be relevant 
in patients with locally advanced disease who are treated with combined modality therapy. Here, 
the role of surgery (besides that of chemoradiation therapy) is at stake, and the issue is to select the 
subset of patients who will benefit from surgery. We and others have shown in observational studies 
that metabolic behavior provided by FDG PET appears to have added prognostic value already early 
during systemic therapy.26,27 
To evaluate the clinical relevance of such metabolic patterns, randomized controlled trials are re-
quired. The issue of these trials will now go beyond the impact of a diagnostic test on TNM-stage 
related outcomes such as futile surgery towards that of the diagnosis-intervention combination to 
improve survival. 
The following sentences may summarize this thesis: to actually evaluate (cost-) effectiveness of diag-
nostic devices, studies are needed that focus on clinical relevant endpoints beyond diagnostic accu-
racy. It is argued and shown that in particular randomized controlled trials can produce results that 
are convincing and directly applicable in clinical practice. The framework of studies presented here 
may support the evaluation of other diagnostic devices.
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Positron Emissie Tomografie (PET) is een betrekkelijk nieuwe nucleair geneeskundige beeldvor-
mende techniek die het mogelijk maakt om biochemische processen in weefsels zichtbaar te maken. 
Om die reden kan PET een complementaire rol spelen bij traditionele beeldvormende technieken 
zoals ‘computed tomography’ (CT) en ‘magnetic resonance imaging’ (MRI) die anatomische infor-
matie opleveren.
Toen het VU Medisch Centrum in 1996 overging tot de aanschaf van een PET-scanner werd be-
sloten de klinische wetenschappelijk aandacht te richten op het identificeren van kosteneffectieve 
toepassingen in de klinische praktijk. Dit proefschrift biedt de theoretische ondersteuning voor dit 
proces en beschrijft haar toepassing bij niet-klein-cellige longkanker.
In hoofdstuk 1 wordt ingegaan op de complexiteit van diagnosticeren en stadiëren in het algemeen 
en bij niet-klein-cellige longkanker (NSCLC) in het bijzonder. In een recent cohort onderzoek, uit-
gevoerd in twee ziekenhuizen in de relevante geografische regio, werden tekortkomingen gevonden 
in de routinematige diagnostiek bij longkanker.1 In bijna 50% van de geopereerde patiënten bleek de 
chirurgische interventie niet geslaagd vanwege niet-verwijderbaar tumorweefsel, goedaardige aan-
doeningen of omdat de ziekte binnen een jaar terug kwam of de patiënt overleed in die periode. In 
dezelfde periode lieten elders studies naar PET met 18F-fluorodexoyglucose als ‘tracer’ (FDG-PET), 
veelbelovende resultaten zien wat betreft de accuratesse voor verschillende aspecten van NSCLC-
stadiëring.2 Echter, betere accuratesse betekent niet automatisch dat het klinisch bruikbaar is, dat 
wil zeggen dat het leidt tot betere diagnostiek en behandeling van patiënten en uiteindelijk tot be-
tere uitkomsten.3 
Het evalueren van de waarde van een diagnostische test kan over het algemeen het best geschie-
den volgens een gefaseerd hiërarchisch proces, zoals in de literatuur beschreven door Fryback en 
anderen.4 Een dergelijk proces omvat een vijftal niveaus: technische aspecten, zoals kwaliteit van 
de beelden en reproduceerbaarheid – meerwaarde op het diagnostisch inzicht –, invloed op behan-
delingsbeslissingen, uitkomsten voor patiënten en als hoogste niveau geldt een kosten-batenanalyse 
bij introductie van de nieuwe test. Het aantonen van effectiviteit op een bepaald niveau is een voor-
waarde, maar is op zichzelf geen garantie, voor effectiviteit op een hoger niveau. 
Gegeven de veelbelovende resultaten van de accuratesse studies en geleid door het resultaat van een 
modelmatige studie naar de kosteneffectieve toepassing van de nieuwe test,5 waren wij van mening 
dat de toegevoegde waarde van FDG-PET het best kon worden bestudeerd door gelijktijdig het 
huidige diagnostische beleid te vergelijken met hetzelfde beleid, maar waar dan FDG-PET aan toe-
gevoegd zou zijn. Om mogelijke verstoringen door verschillen in patiënt- of tumorkarakteristieken 
zo klein mogelijk te maken leek een gerandomiseerde studie (RCT) de meest geschikte studieopzet 
(zoals ook gebruikelijk bij studies naar nieuwe geneesmiddelen). 
Om het begrip ten aanzien van de potentiële invloed van PET op diagnostisch handelen en op be-
handelingsbeleid in de pre-operatieve situatie van NSCLC te vergroten hebben een we eerst een 




artsen – gaande het diagnostische proces – verzocht aan te geven wat hun diagnostische begrip 
was en welke behandelingsstrategie ze zouden volgen net voor, meteen na en 3 maanden na het 
verkrijgen van de resultaten van de PET-scan. Patiënten, verdacht van NSCLC, werden naar het 
PET centrum verwezen indien niet-invasieve testen een bepaald diagnostisch probleem, meestal van 
radiologische aard, niet hadden kunnen oplossen. Op basis van 164 patiënten liet de studie zien dat 
PET een gunstige invloed had op het diagnostische begrip in 84% van de patiënten en dat, volgens 
de clinici, PET het behandelingsbeleid in 50% in positieve zin had bepaald. Afstel van chirurgie op 
basis van PET werd het meest frequent gerapporteerd. PET bleek een sleutelrol te hebben gespeeld 
bij 1 op de 4 patiënten in de studie.
Ten behoeve van het ontwerp van de diagnostische RCT voerden we een literatuuranalyse uit (in 
1996 en herhaald in 2005) om andere diagnostische RCTs (D-RCTs) te vinden. In hoofdstuk 3 
worden de resultaten van die zoekactie gepresenteerd. We ontwikkelden een taxonomie van diag-
nostische RCTs op basis van de vergelijking binnen studies en de uitkomstmaten. De taxonomie 
maakte het mogelijke om eventuele veranderingen in de tijd, in uitkomstmaten in relatie tot de 
beeldvormende testen, te onderzoeken. De eerste zoekactie omvatte 3 verschillende jaren over een 
tijdspanne van 1990 tot 2002. De tweede zoekactie was volledig gericht op studies waarbij MRI als 
diagnostisch instrument onderwerp van studie was, en omvatte in de gehele periode van 1990 tot 
en met 2005. MRI kan worden beschouwd als de meest recente tomografische beeldvormende tech-
niek vòòr de komst van PET en we verwachtten overeenkomsten in de evaluatiemethoden. Uit de 
aspecifieke zoekactie naar D-RCTs bleek dat het grootste deel van de gevonden studies betrekking 
had op het vergelijken van ‘tracers’ of technische uitvoeringskenmerken behorende bij een enkel 
diagnostische instrument. Uiteindelijk konden we slechts 15 D-RCTs vinden waarin patiëntuitkom-
sten werden bestudeerd. De ziekte-indicaties varieerden van cardiovasculaire en gewricht- en spier-
problemen tot kanker. In de tweede zoekactie, die in totaal 16 jaar omvatte, vonden we 13 unieke 
RCTs waarin de waarde van MRI werd onderzocht. Vier van deze studies werden gepubliceerd in 
2005 en 4 in de periode van 2000 tot 2005. In 3 van de 13 studies werden twee onderzoekstechnieken 
in dezelfde patiënt toegepast. In de overige 10 studies werden de patiënten willekeurig verdeeld over 
de beide strategieën. Op basis van de resultaten concluderen we onder andere dat, hoewel in veel 
literatuur aangehaald als optimale methode voor de evaluatie van diagnostische technieken, RCTs 
niet met regelmaat worden uitgevoerd. Daardoor ontbreekt in het algemeen het bewijs voor een 
(kosten-)effectieve toepassing van beeldvormende technieken. 
Omdat het literatuuronderzoek liet zien dat D-RCTs schaars zijn en zeker op het gebied van PET 
nog niet was uitgevoerd, achtten we het van belang om het ontwerp en de logistiek van de studie te 
publiceren (hoofdstuk 4).7 De studie kreeg als acroniem de naam PLUS mee (PET in LUng cancer 
Staging). Om aan de studie deel te nemen moesten de patiënten aan een aantal criteria voldoen: zo 
moest onder andere sprake zijn van een verdenking op, of bewezen NSCLC op basis van klinische 
stadiering (klinisch stadium I-III) en de patiënten moesten medisch operabel en potentieel resecta-
bel zijn naar het oordeel van de plaatselijk behandelend longarts. Net voordat een invasieve ingreep 
(diagnostisch of therapeutisch) aan de orde kwam werden de patiënten willekeurig ingedeeld in 
de groep ‘conventionele strategie’ of ‘conventionele strategie met PET-scan’. Veel aandacht werd 
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besteed aan de definitie van het eindpunt. Als primair eindpunt werd gekozen voor het verschil in 
aantal ‘onnodige of onterechte’ chirurgische ingrepen (thoracotomieën) tussen beide groepen. Een 
thoracotomie werd onnodig of onterecht geacht indien er sprake was van: goedaardige aandoenin-
gen, pathologisch bewezen mediastinale lymfeklieren (stadium IIIA-N2), stadium IIIB of hoger, 
exploratieve chirurgie of terugkerende ziekte of sterfte binnen één jaar na randomisatie. Het proto-
col vereiste pathologische bevestiging van beleidsbepalende PET-positieve verdachte laesies. Naast 
secundaire eindpunten als morbiditeit en duur van het diagnostische proces werd een kostenana-
lyse gepland. De studie werd zodanig ontworpen dat met 95% zekerheid een absoluut verschil van 
25% in het aantal thoracotomieën zou kunnen worden vastgesteld (met onderscheidend vermogen 
van 90%), uitgaande van 45% onterechte thoracotomieën in de huidige situatie (zoals uit het voor-
onderzoek was gebleken). Analyses zouden worden uitgevoerd volgens het ‘intention-to-diagnose’ 
principe (patiënten worden in de analyses meegenomen bij de groep waar ze volgens randomisatie 
aan toe behoren).   
In één enkel jaar werden 188 patiënten uit 9 verschillende ziekenhuizen in de studie opgenomen.8 
Gegevens uit de kankerregistratie van de IKA-regio suggereren dat dit aantal overeenkomt met 65% 
van de potentieel beschikbare populatie in dat jaar. 96 patiënten werden ingedeeld in de ‘conventi-
onele strategie’-groep (CWU) en 92 in de ‘conventionele + PET’-groep (hoofdstuk 5). In beide 
groepen had 70% van de patiënten een stadium I of II ziekte. Een significant kleiner deel van de 
patiënten in de CWU+PET-groep onderging een onterechte thoractomie in vergelijking met de 
CWU-groep. De relatieve afname bedroeg 51% (p = 0.003) en de absolute afname 20% (41% van 
de thoracotomieen in de CWU-groep bleek onterecht). Dit resultaat betekent in de praktijk dat 
op elke 5 patiënten die een PET-scan ondergaan één onterechte thoracotomie wordt voorkomen. 
In 81% van de gevallen suggereerde PET terecht het doen van een thoracotomie en in 71% om er 
terecht van af te zien. Het belangrijkste effect van PET was het tonen van meer ziektelast, ofwel een 
hoger stadium. 
Tegelijkertijd met de medische gegevens werden gegevens over kosten verzameld. Onder kosten wer-
den gerekend, alle invasieve en niet-invasieve testen (inclusief PET), longoperaties en het aantal da-
gen ziekenhuisverblijf. De kosten werden berekend op individuele basis en op ziekenhuisniveau. De 
kosten met betrekking tot PET omvatte personele kosten, afschrijving- en onderhoudskosten, mate-
riaal (FDG) en overhead. De kostprijs van een PET-scan varieerde van € 736 and € 1.588, afhankelijk 
van het type ziekenhuis en de FDG-beschikbaarheid (hoofdstuk 6).9 In de ‘CWU’ groep bedroe-
gen de gemiddelde kosten per patiënt € 9.573 en in de CWU+PET groep € 8.284. De belangrijkste 
kostenpost bleek het aantal hersteldagen in het ziekenhuis na chirurgie. Uit sensitiviteitsanalyses, 
op basis van variaties in de effectiviteit van PET (betrouwbaarheidsintervallen uit de PLUS studie), 
bleek dat de resultaten van de kostenanalyse robuust zijn in het voordeel van PET. In aanvulling op 
de kostenanalyse van de PLUS-studie onderzochten we drie scenario’s waarbij verschillende parame-
ters van PET en de ziekenhuissituatie werden gevarieerd. In een ‘dure’ variant werd uitgegaan van 
PET in een universitaire setting, met FDG-productie ter plekke en PET-scans voor zowel klinische- 
als onderzoeksdoeleinden. Als een ‘goedkope’ variant werd de situatie gekozen van een algemeen 




wordt betrokken. De ‘tussen-in’ variant vertegenwoordigde een groot regionaal ziekenhuis waar 
FDG ter plekke beschikbaar is, 8 PET-scans per dag worden gemaakt en slechts beperkt onderzoek 
wordt verricht. Alle scenario’s, uitgaande van de puntschatting van de effectiviteit van PET,  vielen 
gunstig uit voor PET. Alleen bij de minste effectiviteit van PET (1 onterechte operatie voorkomen 
tegen 14 PET-scans) in de duurste variant (universiteit) bleek de conventionele aanpak goedkoper 
(namelijk € 542).
Niet alle experts onderschrijven de noodzaak voor randomisatie bij diagnostische studies.10 Onno-
dig gebruik van middelen en ethische bezwaren worden zelfs gebruikt als argumenten tegen het doen 
van RCTs. Dit zette ons ertoe aan om onze ideeën over het nut en de noodzaak van gerandomiseerd 
diagnostisch onderzoek uiteen te zetten (hoofdstuk 7).11 Samenvattend stellen wij dat de mate 
waarin een patiënt uiteindelijk voordeel heeft bij het toepassen van een diagnostisch instrument 
(in termen van iatrogene toxiciteit of verbetering in overleving) het best kan worden onderzocht 
door gelijktijdige vergelijking met de bestaande klinische praktijk zonder dat daar onrealistische of 
niet-verifieerbare aannames voor hoeven te worden gemaakt. De meest efficiënte strategie daartoe 
is, om de patiënten willekeurig te verdelen over de conventionele strategie met of zonder de nieuwe 
diagnostiek, waardoor bekende en deels onbekende maar bepalende factoren evenwichtig worden 
verdeeld en de test als enige variabele overblijft. Daarnaast is het van belang om voldoende patiën-
ten in de studie op te nemen. Het opzetten van gerandomiseerde studies brengt bovendien andere 
voordelen met zich mee die niet zozeer met het randomiseren zelf te maken hebben, maar met in-
trinsieke factoren als transparantie, doordat een duidelijk protocol aan de studie ten grondslag ligt 
en het opstellen van hypotheses met bijbehorende berekeningen voor de steekproefgrootte.
De twee gerandomiseerde studies met FDG-PET bij longkanker laten zien dat dergelijke pragmati-
sche RCTs uitvoerbaar zijn. In de PLUS studie werden 188 patiënten, met stadium I-III, in één jaar 
geincludeerd. De POORT studie, waarbij de rol van FDG-PET vroeg in het diagnostische traject 
werd gepositioneerd ter mogelijke vervanging van andere testen, werden in minder dan twee jaar 
tijd 465 patiënten aangemeld.12 Het feit dat FDG-PET in die tijd nog weinig beschikbaar was heeft 
mogelijk wel bijgedragen aan dit succes.
Hoofdstuk  is een omvattend geheel van onze ervaring ten aanzien van de evaluatie van de kostenef-
fectiviteit van FDG-PET voor verschillende indicaties. Het vormt een raamwerk, wat in grote lijnen 
de hiërarchische aanpak voor de waardebepaling van diagnostische studies zoals eerder hierboven 
beschreven is, volgt. Het startpunt van onze studies was de geconstateerde inefficiëntie bij conven-
tionele diagnostiek waarbij de betere accuratesse van FDG-PET, zoals gesuggereerd, mogelijk winst 
zou kunnen opleveren. Het retrospectieve cohortonderzoek toonde de aard van de problematiek 
en betekende een belangrijke motivering voor de clinici om aan verder onderzoek mee te werken. 
De ‘aanloop’-studie naar de klinische waarde van PET vormde de leercurve voor diagnostici en be-
handelaars. Uiteindelijk droeg de opeenvolging en samenhang van de studies bij aan een vruchtbare 
samenwerking wat naar onze mening de RCTs en het ontwikkelen en implementeren van richtlijnen 
in de regio ten goede kwam. 
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het heden
Anno 2006 is de PET-situatie in Nederland wezenlijk anders. De PET-scanner-capaciteit is enorm 
toegenomen en momenteel hebben de meeste ziekenhuizen toegang tot of de beschikking over een 
vaste of mobiele PET. In de Amsterdamse regio zijn in een straal van 20 kilometer tenminste 5 scan-
ners. Vanaf 2004 bevatten de nationale richtlijnen voor diagnose en behandeling van niet-kleincel-
lige longtumoren regels voor het gebruik van FDG-PET.13 Voortdurend worden deze richtlijnen 
door middel van studies aangescherpt. Geschat wordt dat in ongeveer 80% van de patiënten, met 
een verdenking op operabele NSCLC, een PET-scan deel uit maakt van de reguliere diagnostiek. 
Een recente analyse van de gegevens uit de kankerregistratie van het Integraal Kankercentrum Am-
sterdam suggereert een absolute afname van 20% in het aantal longoperaties sinds 2000 (wat over-
eenkomt met een relatieve afname van 50% in onnodige operaties) vergeleken met de 5 voorgaande 
jaren.14 
Sinds de opkomst van de PET-scanner hebben verbeteringen in het concept van de scanner en an-
dere nieuwe technologieën het licht gezien. Na 15 jaar ‘whole-body’ PET is recentelijk een geïnte-
greerde of hybride PET-CT scanner geïntroduceerd.15-17 Verschillende studies hebben superieure 
accuratesse gesuggereerd voor deze geïntegreerde PET-CT in vergelijking met het afzonderlijk vi-
sueel beoordelen van CT en PET-beelden (zoals gebruikelijk bij de PLUS-studie). Een eenvoudi-
ge zoekactie in MEDLINE leverde 5 studies op die de accuratesse van de geïntegreerde PET-CT 
scanner onderzochten in vergelijking met andere technieken in longkanker.18-22 Alle 5 suggereerde 
een verbeterde accuratesse met PET-CT vergeleken met het afzonderlijk beoordelen van de beel-
den en twee studies claimden veranderingen in behandeling van patiënten op basis van de hybride 
PET-CT.18,19 Echter, de eerste vraag die zou moeten worden gesteld is wat de aard en de mate van 
inefficiëntie is bij de huidige diagnostiek, waarbij inmiddels de PET wordt gebruikt. Hoewel we 
er vertrouwen in hebben dat het aantal longoperaties is afgenomen door de toevoeging van PET, 
weten we uit de PLUS studie dat nog steeds 20% van de operaties niet zinvol is. Om in te schatten 
of de geïntegreerde PET-CT iets van deze 20% onnodige operaties af had kunnen halen hebben we 
naar de individuele gevallen uit de PLUS studie gekeken: in 9 patiënten bleek de longoperatie zelf 
niet zinvol te zijn en in 10 andere patiënten kwam de ziekte vroeg terug of stierven de patiënten bin-
nen één jaar. Van de 9 patiënten bij wie de operatie zelf al onnodig bleek hadden 2 een goedaardige 
aandoening, 6 hadden N2 ziekte of erger en 1 patiënt kon niet afdoende worden geopereerd wegens 
onvoldoende longcapaciteit. Van de 6 patiënten bij wie peroperatief een hoger een stadium werd 
aangetroffen bleek in 3 gevallen een mediastinoscopie de verdenking in de lymfeklieren, zoals gesug-
gereerd door de PET, niet te kunnen bevestigen. In de 10 patiënten waarbij in de follow-up duidelijk 
werd dat de chirurgie onnodig was, kwam bij 4 patiënten de ziekte vroeg terug na ogenschijnlijk 
curatieve chirurgie. Twee patiënten kregen botmetastasen en één hersen- en botmetastasen na het 
weigeren van een PET en bij de laatste patiënt bleken longmetastasen van een melanoom (primaire 




overleden aan oorzaken gerelateerd aan de chirurgie en bij één was de doodsoorzaak onbekend. 
Concluderend had een betere niet-invasieve diagnostiek met PET-CT dus hooguit bij 3 van de 19 
patiënten een onnodige operatie kunnen voorkomen. We realiseren ons dat deze aantallen te klein 
zijn voor definitieve conclusies, maar het geeft een indruk van de te verwachten winst van PET-CT 
bij het voorkomen van onnodige operaties. 
Vergeleken met PET alleen, draagt PET-CT zeker bij aan de specificiteit van PET-interpretatie met 
als mogelijk klinisch gevolg dat biopsieën ter bevestiging van kwaadaardigheid efficiënter kunnen 
worden uitgevoerd. In de PLUS-studie bleken PET-positieve lagere cervicale lymfeklieren moeilijk 
te bevestigen door radiologen in de algemene ziekenhuizen. Echter, het mislukken van de bevestigen-
de procedures heeft het aantal onnodige operaties niet beïnvloed, aangezien dergelijke lymfeklier-
verdenking ook op andere manieren bevestigd kan worden (zij het wat invasiever). Wat betreft de 
waarde van PET-CT op de sensitiviteit: we hebben beredeneerd dat test-resultaten zelden tweeledig 
zijn en daarom kan PET-CT, ondanks dat het is opgebouwd uit dezelfde PET en CT-componenten 
als in de enkelvoudige opzet, het kwartje doen kantelen naar een hoger niveau van waarschijnlijk-
heid. Echter, wanneer de redenering ten aanzien van problemen die blijven na gebruik van PET op 
basis van de PLUS-studie klopt, dan verwachten we geen enorme verbetering hierin. Beweringen 
over verbeterde stadiering op het gebied van de primaire tumoruitbreiding22 moeten nog worden 
bevestigd, gezien de beperkte resolutie van PET.23 Alternatieve manieren om het mediastinum pre-
operatief te onderzoeken geven meer hoop voor de toekomst. Endoscopische echografie met naald 
punctie vanuit de slokdarm of vanuit de bronchus (EUS-FNA en EBUS-FNA) zijn nieuwe mini-
maal invasieve technieken met hoge potentie voor het beoordelen van klieren in het mediastinum 
en centraal gelegen tumoren.24 
In het geval van PET-CT kunnen ook logistieke factoren de overstap naar deze modaliteit recht-
vaardigen, zelfs wanneer verbetering op klinisch gebied of lagere kosten onwaarschijnlijk zijn, of 
moeilijk aan te tonen. Het concept van stadieren met één enkele scan (‘one-stop-shop’) in plaats van 
door een hele batterij aan testen over een langere periode is erg aantrekkelijk voor zowel de patiënt 
als vanuit het perspectief van de behandeling. Bovendien zal een kortere PET-scan tijd ook worden 
gewaardeerd door hen die momenteel met wachtlijsten te maken hebben.
Hoe het ook zij, welke methodologische bezwaren we ook mogen hebben ten aanzien van de be-
wijsvoering van de superioriteit van PET-CT ten opzicht van PET, de industriële ontwikkeling is 
nu eenmaal zo dat binnenkort de PET-CT de standaard is, eenvoudigweg omdat enkelvoudige PET-
scanners niet meer worden verkocht.
Eén van de vragen die dan speelt, is of PET-CT aan het begin van diagnostisch traject moet worden 
ingezet of juist net voor het (invasieve) onderzoek van het mediastinum: het is niet economisch om 
een PET-CT-scan bij elke patiënt te maken, wanneer alleen al op basis van CT-bevindingen een 
groot aantal van de patiënten kunnen worden uitgesloten voor chirurgie. Modelmatige analyses, bij 
voorkeur gebaseerd op informatie over werkelijke kosten en scenarioanalyses kunnen bijdragen aan 
de oplossing van dit probleem. 
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Tot nu toe is FDG-PET aan bod gekomen in de context van chirurgische beslissingen enkel geba-
seerd op TNM-stadiërings kwesties. Echter, de door PET verkregen metabole informatie lijkt ook 
prognostische informatie toe te voegen binnen de klinische stadia25: hoge opname door tumoren 
blijkt prognostisch ongunstig in vergelijking met lage opname. Ondanks dat het ontbreken van 
standaardisering van kwantitatieve PET-procedures, hetgeen het uitvoeren van meta-analyses van 
individuele studies bemoeilijkt, lijkt dit toch een consistente bevinding. Hoe deze informatie kan 
worden gecombineerd met andere prognostische factoren teneinde strategieën te ontwikkelen om 
de relatief slechte uitkomsten van patiënten met operabele NSCLC te verbeteren valt nog te bezien. 
Het komt waarschijnlijk neer op systemische therapieën voor specifieke subgroepen. Een vergelijk-
baar prognostische aspect van PET is mogelijk relevant bij patiënten met lokaal uitgebreide ziekte 
die worden behandeld met combinatie therapieën. De rol van chirurgie staat hierbij ter discussie en 
mogelijk kunnen subgroepen van patiënten worden geïdentificeerd die baat hebben bij chirurgie. 
In observationele studies hebben wij, en anderen ook, laten zien dat het metabole gedrag, in beeld 
gebracht met PET, al vroeg tijdens systemische therapie, een voorspellende waarde kan hebben.26,27 
Om de klinische relevantie van dergelijke metabole patronen te bepalen zijn wederom gerandomi-
seerde onderzoeken nodig. Bij die onderzoeken verschuift de interesse van het bepalen van het effect 
van een diagnostische test op TNM-van gerelateerde uitkomsten, zoals onnodige chirurgie, naar die 
van het effect van diagnose-behandel-combinaties op de verbetering van overleving.
Met de volgende zinnen kan het proefschrift worden samengevat: voor het evalueren van (kosten-) 
effectiviteit van diagnostische technieken zijn studies nodig die zich richten op klinisch relevante 
eindpunten voorbij de accuraatheids parameters. Beargumenteerd en getoond wordt dat gerando-
miseerde klinische studies in het bijzonder resultaten kunnen voortbrengen die overtuigen en direct 
toepasbaar zijn in de praktijk. Het raamwerk van studies dat hier wordt gepresenteerd kan van nut 
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